

GENOMICS TODAY

Molecular Genetics & Cytogenomic Disorders

PATHOLOGY FINAL PROJECT
2026 • GROUP 41



FROM THE EDITOR

Decoding Life: Why Genetics Matters Now

Somewhere inside the nucleus of nearly every cell in your body — a space so small it would take ten thousand of them laid end-to-end to span the width of a human hair — an extraordinary molecule lies coiled, waiting. Three billion letters long. Read in full, it would fill a library. And yet your cells *read it every day*, flawlessly, at breathtaking speed, responding to signals from the world outside.

That molecule is your genome. And in this issue of Genomics Today, we set out to do something ambitious: to make it feel as wondrous as it actually is.

The past two decades have brought a revolution to genetics — from the triumphant completion of the Human Genome Project in 2003, to the era of *affordable whole-genome sequencing*, to CRISPR, to drugs that reach directly into a malfunctioning protein and fix it. Genetics has moved from the bench to the bedside. The stakes have never been higher, or the science more alive.

All of our content is drawn faithfully from peer-reviewed scientific sources. Every fact is grounded there. But we have tried to tell it differently: not as a catalogue of disorders, but as a story. The story of how life encodes, copies, miscopies, repairs, regulates and — occasionally, spectacularly — goes wrong.



We hope you find, somewhere in these pages, the thing that originally lit the spark for science: the sudden, undeniable sense that the world is stranger and more marvellous than you had supposed.

All content is drawn from accredited sources for educational purposes only.



CONTENTS

Molecular Genetics & Cytogenomic Disorders

FEATURES

The Human Genome: A Blueprint in 3 Billion Letters	15
Chromosomal Architecture: How Structure Shapes Disease	16
Epigenetics: Beyond the DNA Sequence	19
The Genetics of Childhood and Congenital Disorders	20

EXPLAINERS

Types of Mutations: From Single Bases to Whole Chromosomes	26
Aneuploidy at a Glance	30
Mendelian vs Non-Mendelian Inheritance	32
Mitochondrial Genetics and Energy Disorders	33
Trinucleotide Repeat Expansion: When DNA Forgets to Stop	36

TECHNIQUES

Karyotyping: Seeing Chromosomes in Action	38
FISH: Fluorescent Windows into the Genome	39
Microarray: The Copy-Number Map	40
PCR & Sequencing: Sanger vs NGS	43
Cancer Genomics: Mutations that Drive Tumors	44

CASE STUDIES

WAGR Syndrome: The Story of 11p13	47
Cystic Fibrosis and CFTR Δ F508	48
Huntington's Disease: CAG Repeats and Neurodegeneration	49
Fragile X Syndrome and FMR1 Silencing	50
Philadelphia Chromosome and the Birth of Targeted Therapy	51

SHORT NOTES & REFERENCE

Haploinsufficiency Mosaicism Imprinting Somatic vs Germline	53
Glossary of Genetic Terms	54
References	56
Image References	68



The Human Genome at a Glance

The scale of the human genome is almost incomprehensible. These key figures frame the biological canvas on which all of genetics operates – from single-base mutations to whole-chromosome aneuploidies.

~3.2B

Base pairs
per haploid set

~25,000

Protein-coding
genes

1.5%

Coding fraction
of the genome

46

Chromosomes in
a diploid cell


2.4M bp

Largest gene
DMD (dystrophin)


99.9%

DNA shared between
any two humans


DNA HIERARCHY: FROM DOUBLE HELIX TO CHROMOSOME



Hierarchical organization of genomic DNA from double helix to mitotic chromosome.



Lung cancers in smokers are strongly associated with mutations in genes like KRAS and TP53. Lung cancers in non-smokers often involve EGFR mutations




Melanoma is often driven by genetic mutations—most commonly in the BRAF gene—that disrupt normal cell growth, turning healthy pigment cells into cancerous ones.

A Century of the Genome

The Innovations That Changed Everything

From the first glimpse of chromosomes under a light microscope to the era of CRISPR gene editing and precision medicine — a chronicle of the discoveries that built modern genomics, and the scientists who made them possible.



ERA 1 OF 5

1953 – 1970

The Cytogenetics Era

When scientists first laid eyes on the chromosome — and began to read what it meant

1953

Watson & Crick — The Double Helix

Building on Rosalind Franklin's X-ray crystallography data (Photo 51), Watson and Crick published the double-helical structure of DNA in *Nature* — a single page that restructured all of biology. The antiparallel complementary strands immediately suggested a copying mechanism.¹

STRUCTURE

Nobel Prize

1959

Lejeune — Trisomy 21 Causes Down Syndrome

Jerome Lejeune demonstrated that Down syndrome results from three copies of chromosome 21 — the first time a specific chromosomal abnormality was linked to a human condition.³ Turner (45, X) and Klinefelter (47, XXY) syndromes were characterised the same year.

ANEUPLOIDY

1956

Tjio & Levan — 46 Chromosomes Confirmed

For thirty years, textbooks taught that humans carry 48 chromosomes. Tjio and Levan, using improved tissue culture and hypotonic treatment, established the correct diploid number of 46.² The cytogenetic age had truly begun.

CYTOGENETICS

ERA 2 OF 5

1970 – 1990

The Molecular Revolution

Restriction enzymes, recombinant DNA, and the first tools to cut, clone, and read the genetic code

1973

Cohen & Boyer — Recombinant DNA

Stanley Cohen and Herbert Boyer inserted foreign DNA into a bacterial plasmid and produced the first recombinant DNA organism. Genetic engineering was born.⁶ Janet Rowley also characterized the Philadelphia chromosome as a true reciprocal translocation — t(9;22) — rather than a simple deletion.⁷

ENGINEERING

1970

Restriction Enzymes Isolated

Hamilton Smith isolated the first type II restriction enzyme (HindII), which cuts DNA at specific sequences.⁴ These molecular scissors made it possible to dissect any genome at predictable positions — the prerequisite for everything that followed.

TOOL

Nobel Prize

1977

Sanger — Dideoxy Sequencing (Chain Termination)

Frederick Sanger published the dideoxy chain-termination method for DNA sequencing — simultaneously with the Maxam-Gilbert chemical method.⁸ Sanger's method prevailed. By 1977, he had sequenced the entire 5,375-base genome of bacteriophage phiX174 — the first complete genome of any organism.⁹

SEQUENCING

Nobel Prize

ERA 3 OF 5

1990 – 2003

The Sequencing Age

The Human Genome Project and the race to read three billion letters

1993

HTT Gene – Huntington's CAG Repeat Expansion

The Huntington's Disease Collaborative Research Group identified the HTT gene and the pathological CAG repeat expansion responsible for Huntington's disease – the first disease gene identified purely through positional cloning without any prior knowledge of protein function.¹¹

DISEASE GENE

1990

Human Genome Project Launched

An international consortium of 20 research centres across 6 countries formally launched the Human Genome Project – with the goal of sequencing all 3 billion base pairs within 15 years. Budget: \$3 billion.¹⁰ Anticipated by many as the most ambitious biology project in history.

HGP

1994–95

BRCA1 & BRCA2 Cloned

BRCA1 (1994) and BRCA2 (1995) were isolated and sequenced, revealing the genetic basis for hereditary breast and ovarian cancer.^{12,13} Lifetime breast cancer risk for BRCA1 carriers: 55–70%.¹⁴ Genetic counselling and risk-reducing surgery became central to oncology care.

CANCER GENETICS

ERA 4 OF 5

2003–2012

Genomics & the Post-Genome Era

Arrays, next-generation sequencing, and the transformation of clinical diagnostics

2007

Chromosomal Microarray Replaces Karyotype for ID

Array CGH achieved kilobase-resolution genome-wide copy-number analysis from a single experiment — detecting pathogenic CNVs in ~15–20% of children with unexplained intellectual disability, far exceeding the ~5% yield of karyotyping.¹⁷ In 2010, ACMG recommended CMA as first-line.¹⁸

DIAGNOSTICS

2005

Next-Generation Sequencing Platforms Launch

454 Life Sciences launched the first commercial next-generation sequencing platform — massively parallel sequencing of hundreds of thousands of fragments simultaneously.¹⁵ Illumina's Solexa platform (2006) followed. The cost of sequencing a human genome began its 100,000-fold decline.¹⁶

NGS

2010

Whole-Exome Sequencing Enters Clinical Practice

WES — sequencing all ~20,000 protein-coding exons simultaneously — began delivering diagnoses in 25–40% of patients with previously undiagnosed rare diseases.^{19,20} The "diagnostic odyssey" — in which families waited years for a diagnosis — began to shorten measurably for the first time.²¹

CLINICAL WES

ERA 5 OF 5

2012–2024

Precision Medicine & Gene Editing

*CRISPR, CFTR modulators, polygenic scores —
genomics moves from the laboratory to the bedside*

2012

Doudna & Charpentier — CRISPR-Cas9 as a Programmable Editor

Jennifer Doudna and Emmanuelle Charpentier published the landmark description of CRISPR-Cas9 as a programmable genome editing tool — capable of making precise cuts at any genomic location specified by a short guide RNA.²² The ability to edit any gene in any organism arrived in a single paper.

GENE EDITING

Nobel Prize

2019

Trikafta (ETI) — CFTR Modulator Transforms Cystic Fibrosis

FDA approval of elexacaftor/tezacaftor/ivacaftor for CF patients with at least one $\Delta F508$ mutation expanded eligibility to ~90% of patients.²⁵ Clinical trials showed ~14% FEV1 improvement, major reductions in exacerbations, and better quality of life.²⁶ CF went from a fatal childhood disease to a largely manageable condition for most.


PRECISION THERAPY

2013

The \$1,000 Genome — Illumina HiSeq X Ten

Illumina announced the HiSeq X Ten system, capable of sequencing a human genome for under \$1,000 — a threshold that had seemed distant in 2003 when the cost was \$3 billion.^{23,24} The economics of clinical whole-genome sequencing had transformed irreversibly.

COST MILESTONE



OFFICIAL LAUNCHING

ON MARCH 15th, 44 BC


THE KRONOS 6.0

BECAUSE GOOD TIMING...
RUNS IN THE FAMILY.



PREMIUM
STAINLESS STEEL WATCH

MCCLINTOCK CO.



§

FEATURES

The human genome, chromosomal architecture, epigenetics, and congenital disorders — building the conceptual foundation of modern genetics.

The Human Genome

A Blueprint in 3 Billion Letters

Three billion base pairs. Twenty-five thousand genes. And yet the instructions for building an entire human being fit inside a nucleus smaller than a hair's width – a feat of compression that no human engineer has come close to replicating.

Picture the scene. Deep inside a cell, invisible to the naked eye, a molecule two metres long lies coiled in a space one ten-thousandth of a millimetre across. It does not simply sit there. It is read, copied, repaired, silenced, activated. It responds to hunger, to sunlight, to stress. It has been doing this, without interruption, since the moment that cell first came into being. It is, quite possibly, the most extraordinary thing on Earth.

That molecule is DNA. And its story – the genome's story – is what this magazine is about. The human genome contains approximately 3.2 billion base pairs of DNA distributed across 23 pairs of chromosomes, encoding an estimated 20,000–25,000 protein-coding genes.²⁷ And yet – here is the twist that took biologists decades to absorb – protein-coding sequences represent only about 1.5% of the total genome.²⁷ The other 98.5% was once dismissively called "junk DNA."^{28,29} We now know it is anything but.

That vast noncoding territory – introns, regulatory elements, repetitive sequences, stretches of ancient viral DNA woven into our chromosomes millions of years ago – turns out to be an exquisitely tuned control system.³⁰ It decides which genes switch on, when, and in which tissues. It is the conductor that makes an orchestra out of 25,000 instruments.

The genome is organized hierarchically. DNA double helices wind around spool-like proteins called histone octamers to form nucleosomes – each resembling a bead on a string.³¹ These nucleosomes coil into chromatin fibers, which loop and condense further into the chromosome arms visible under a light microscope at metaphase.³¹ At each level, structure encodes additional information: which genes are accessible, and which are locked away.³¹

The completion of the Human Genome Project in 2003 was a watershed moment, celebrated on the front pages of newspapers around the world.³² And yet no matter how comprehensive a DNA test is performed, it can never tell the whole story. The genome is not a simple instruction manual. It is a dynamic, interactive, living document, rewritten in real time by experience and environment. Whole-exome sequencing (WES) and whole-genome sequencing (WGS) now allow clinicians to query every coding variant in a patient's genome – identifying causative mutations in conditions that once defied diagnosis. But reading the letters is only the beginning. Understanding what they mean is a challenge that will occupy geneticists for generations.

KEY GENOME STATISTICS

~3.2 billion base pairs
per haploid set


20,000–25,000 genes
protein-coding

~1.5%
coding fraction of genome

46 chromosomes total
22 autosomes + 2 sex chromosomes

~27,000 bp average
gene size including introns

2.4 million bp
DMD (dystrophin) – largest human gene




Chromosomal Architecture

How Structure Shapes Disease


Look at a human chromosome under a microscope — a thick, stubby X-shape, Giemsa-stained into bands of light and dark — and you are looking at a marvel of packing. Inside that structure: tens of millions of base pairs of DNA, wound and folded and looped into a space small enough to pass through the eye of a needle. And the packing matters. Disrupt it in the wrong place, and the consequences ripple outward across whole systems.

Each chromosome has a defined anatomy: two arms (p for short, from the French *petit*; q for long), a centromere at the junction, and telomeres capping each end.³³ The centromere is the chromosome's anchor during cell division — it is where the spindle fibres attach, pulling each chromosome toward its new home in a daughter cell. Telomeres, those repetitive TTAGGG sequences at the tips, protect the chromosome's ends from fraying and fusion, like the plastic caps on a shoelace. They shorten with every cell division, ticking down like a molecular clock toward cellular aging.³⁴



Chromosome banding — achieved by Giemsa (G-banding), quinacrine fluorescence (Q-banding), or reverse banding (R-banding) — reveals a reproducible landscape of light and dark stripes unique to each chromosome.³⁵ The International System for Human Cytogenetic Nomenclature (ISCN) translates this landscape into standardized shorthand: 46, XY is a normal male; 47, XX,+21 is a female with Down syndrome. A single line of code that encodes a life.³³

Structural variants arise from errors in meiotic recombination — moments when chromosomes, crossing over to swap genetic material, slip and misalign.³⁶ Low copy repeats (LCRs) flanking certain genomic regions act like a pair of identical sentences in a paragraph: the cell's molecular machinery, momentarily confused, cuts in the wrong place.³⁶ The result is a deletion or duplication of everything in between. More than 25 recurrent segmental deletion and duplication syndromes have been characterized this way — from the 22q11.2 deletion that underlies DiGeorge syndrome to the 17p11.2 deletion of Smith-Magenis syndrome.^{36,37} Same mechanism, different chromosome, completely different child.



For most polygenic conditions, environmental factors modify risk substantially. In Lynch syndrome, surveillance colonoscopy reduces colorectal cancer mortality by over 60%.³⁸ Knowing your genetic risk often enables the most effective preventive action.




Many genetic diseases are now highly treatable. CFTR modulators transformed cystic fibrosis; imatinib transformed CML; enzyme replacement therapy addresses lysosomal storage diseases.^{25,39} Genetic aetiology does not imply therapeutic nihilism.

Epigenetics: Beyond the DNA Sequence

What if two people carried exactly the same DNA sequence – letter for letter, base pair for base pair – and yet one developed a disease the other never would? What if a gene could be silenced not by mutation, but by memory?

This is not a thought experiment. It is epigenetics – one of the most dazzling revolutions in biology since the discovery of the double helix. Epigenetic mechanisms regulate gene expression without altering the underlying DNA sequence.⁴⁰ They are, in a very real sense, annotations in the margins of the genome: instructions that say "read this," "skip that," "silence this gene forever." And unlike mutations, they can be inherited, reversed, and, crucially, influenced by the environment.⁴⁰

The most studied mechanism is **DNA methylation** – the chemical addition of a methyl group to cytosine at so-called CpG dinucleotides.⁴¹ When a gene's promoter region becomes heavily methylated, it is as if a padlock has been snapped shut: the gene falls silent.^{41,42} This is not dysfunction – it is regulation. Every cell type in your body uses DNA methylation to maintain its identity, to remember that it is a liver cell and not a neuron. But when the system goes wrong – when the padlock is applied to a tumour suppressor gene, or fails to silence a gene that should stay quiet – the consequences can be severe.⁴²



Then there is **histone modification** – the chemistry of packaging. Histone proteins, the spools around which DNA winds, can be modified at their flexible tails in dozens of ways: acetylated, methylated, phosphorylated, ubiquitinated.^{43,44} Each modification alters how tightly the DNA is wound, and therefore how accessible it is to the cellular machinery. Histone acetylation, added by enzymes called HATs, loosens the coil and activates transcription. Deacetylation, performed by HDACs, tightens it back up. Mutations in the enzymes that write and erase these marks – EZH2, SETD2, ARID1A – are now recognized as drivers of both rare Mendelian syndromes and cancer.^{43,45}

Perhaps the most striking example of epigenetics in action is **genomic imprinting** – the phenomenon by which a gene's activity depends not on its sequence, but on whether it came from your mother or your father. At the 15q11–q13 chromosomal region, two entirely different syndromes can arise from dysfunction in the same stretch of DNA – simply depending on which parent's copy is affected.⁴⁶ The genome, it turns out, keeps track of its own history.

The Genetics of Childhood Disorders and Congenital Disorders

Every child that is born begins as a single cell — a zygote, carrying two complete sets of instructions, one from each parent. In the vast majority of cases, the orchestration of development proceeds with flawless precision: a cascade of gene activations and silencings, cell migrations and adhesions, tissue inductions and organ formations, each step triggering the next. But sometimes — silently, invisibly — something goes differently. That is where this chapter of genetics begins.



Congenital disorders arise from prenatal developmental errors. Clinicians classify them by mechanism: **malformations** (primary errors in morphogenesis, where a structure never forms correctly), **deformations** (mechanical forces that distort normally-formed structures — a tight uterus, insufficient amniotic fluid), **disruptions** (something destroys tissue that was forming correctly — a vascular accident, an infection), and **dysplasias** (abnormal cellular organization within a tissue).⁴⁷ These distinctions are not merely academic. They determine the recurrence risk a family faces, and therefore the advice a geneticist can give.


The most diagnostically complex cases are multiple malformation syndromes — where two or more unrelated organ systems are affected by the same underlying cause.⁴⁸ Is it a chromosomal imbalance? A single mutant gene? An environmental exposure? Until recently, many of these children went undiagnosed for years, their families left without answers. Today, **chromosomal microarray (CMA)** has replaced karyotyping as the first-line test for such children, identifying causal copy-number changes in approximately 10% of cases.^{17,18} Whole-exome sequencing (WES) yields a diagnosis in 25–40% of children with unexplained intellectual disability.^{49,50,51} The era of the undiagnosed is, slowly, coming to an end.



Helix Pharmacy

**Trusted
Pharmacy
Caring for You!**

Get expert advice & quality medicines—all in one place!

A high-magnification histological image of breast tissue. The image shows numerous glandular units, each consisting of a cluster of cells with prominent, dark brown nuclei. These glands are separated by a network of light-colored, fibrous stromal tissue. The overall architecture is typical of mammary gland tissue, with the glands appearing as rounded or oval structures. The staining highlights the cellular details and the connective tissue framework.

Having a first-degree relative with breast cancer approximately doubles lifetime risk^{52,53} — but absolute risk for most women remains under 20%.⁵² BRCA1/2 mutations, present in <0.5% of the population⁵⁴, raise this substantially, but most breast cancers occur in women with no such variant.

MENDEL'S




OUR FRUITS
ARE CAREFULLY
SELECTED
FOR THEIR
DOMINANT
FLAVORS AND
RECESSIVE
BITTERNESS,
SO EVERY SIP
EXPRESSES
ONLY THE
BEST TRAITS.



§

EXPLAINERS

Mutation types, inheritance patterns, mitochondrial genetics, and trinucleotide repeat disorders — the mechanics of heredity explained.



"YOUR GENES DETERMINE YOUR DESTINY."

This is, perhaps, the most pervasive misconception in all of genetics — and the most seductive. It has a clean, fatalistic elegance to it. You inherit your genes; your genes make you who you are; therefore the die is cast at conception. The genome, in this telling, is a blueprint not just for a body but for a life.

It is also, as a general statement, wrong.

For single-gene Mendelian disorders — cystic fibrosis, Huntington's disease, Duchenne muscular dystrophy — the relationship between genotype and phenotype is indeed strong.^{55,56} Carry two broken copies of *CFTR* and you will develop cystic fibrosis.^{57,58} Carry more than forty CAG repeats in *HTT* and you will, barring an early death from something else, develop Huntington's disease.^{59,60} In these cases, the determinism is real. But these conditions account for a small fraction of all human disease.

For the vast majority of conditions that cause human suffering — heart disease, type 2 diabetes, schizophrenia, depression, most cancers — genetics contributes risk, not fate.⁶¹ Genome-wide association studies (GWAS) have identified hundreds of variants associated with these conditions, each individually tiny in its effect, collectively explaining perhaps 30–60% of phenotypic variance.^{62,63,64} The rest is environment, behaviour, chance, and the interaction between all three.

A fluorescence microscopy image showing a network of cells. The cells are stained with two different dyes: one in red and one in blue. The red-stained cells form a dense, interconnected web, while the blue-stained cells are more isolated and appear as distinct, rounded structures. The overall image has a dark background, making the brightly colored cells stand out.

"YOUR GENES DETERMINE YOUR DESTINY."

The concept of penetrance is central here. Even mutations that are described as "highly penetrant" — meaning that most people who carry them develop the associated disease — are rarely fully penetrant in all environments.^{65,66} BRCA1 mutations, for example, carry a lifetime breast cancer risk of roughly 55–70% — catastrophically elevated compared to the population average, but still meaning that roughly one in three carriers will not develop the disease. The gene is not the whole story.^{67,68}

Epigenetics has added another layer of complexity. Identical twins — who share their entire DNA sequence — can diverge dramatically in disease risk, personality, and longevity as they age.⁶⁹ The explanation lies in the gradual accumulation of epigenetic differences: differences in which genes are methylated, which histones are modified, which non-coding RNAs are expressed.⁷⁰ The genome is not a static text. It is a dynamic conversation, and what it says depends in part on what it has heard.

Types of Mutations

From Single Bases to Whole Chromosomes

Genetic mutations span an enormous scale – from the substitution of a single nucleotide to the gain or loss of an entire chromosome. Understanding this spectrum is fundamental to clinical genetics because mutation type determines both the diagnostic approach and the likely clinical consequences.

Think of the genome as a three-billion-letter text. A mutation is any change to that text – and the range of possible changes is extraordinary. At one extreme, a single letter is swapped for another: a typo invisible to the eye, yet capable of rewriting a life. At the other extreme, an entire chapter – an entire chromosome – appears twice where it should appear once, or not at all where it should always be present. The scale of the mutation determines what went wrong, how badly, and how we look for it.

Point Mutations (SNVs)

The simplest change: one nucleotide swapped for another.⁷¹ A missense mutation substitutes one amino acid for another in the resulting protein⁷²; a nonsense mutation installs a premature stop codon, truncating the protein mid-sentence⁷³; a splice-site mutation corrupts the signals that tell the cell where to cut and join the pre-mRNA transcript⁷⁴. Consequences range from negligible to catastrophic, depending entirely on which amino acid changes and how critical that position is to the protein's function.⁷¹⁻⁷⁴

Small Indels (Frameshift)

Insertions or deletions of 1–50 base pairs.⁷¹ When the change is not in a multiple of three, the reading frame shifts – every codon downstream is misread, and the protein produced bears no resemblance to the original.⁷¹ The classic $\Delta F508$ mutation in cystic fibrosis is a 3-bp in-frame deletion – no frameshift, yet it removes a single phenylalanine that causes the protein to misfold catastrophically.^{75,76}



Types of Mutations

From Single Bases to Whole Chromosomes

Trinucleotide Repeat Expansions


A peculiar class of mutations in which a short repeated sequence expands, reel by reel, across generations. The replication machinery slips, adding extra copies of the repeat.⁷⁷ Beyond a critical threshold, the expanded sequence triggers disease — sometimes by poisoning the protein with extra glutamine residues, sometimes by silencing the gene entirely.⁷⁸ And because expansions tend to grow larger with each transmission, the disease strikes earlier and harder in each successive generation: a phenomenon called genetic anticipation. It is, in a sense, a gene that worsens with time.⁷⁸


Microdeletions / Microduplications

Genomic rearrangements of 1 kb to 5 Mb, often mediated by non-allelic homologous recombination between flanking low copy repeats.⁷⁹ The cell's repair machinery is confused by identical sequences flanking a region — it loses track of which copy is which, and the sequence between them is lost or duplicated.⁷⁹ The result is a contiguous gene syndrome: the simultaneous haploinsufficiency of every gene in the deleted region.⁷⁹


Aneuploidy

The most dramatic category: the gain or loss of an entire chromosome.⁸⁸ Every gene on that chromosome is present in the wrong dose.⁸⁸ The cell's finely tuned regulatory networks, calibrated for exactly two copies of each gene, are thrown into disarray across hundreds of loci at once.⁸⁸






Nearly all cervical cancers are driven by infection with high-risk types of Human papillomavirus, whose viral genes (E6 and E7) inactivate the TP53 and RB1 tumor suppressor pathways.^{81/82}



Mutations in the TP53 gene—often caused by UV-induced DNA damage—are very common in squamous cell carcinoma and impair the cell's ability to repair genetic errors.^{83,84}





Aneuploidy at a Glance

DURING MEIOSIS — the specialized cell division that creates eggs and sperm — something remarkable and perilous must happen.^{80,85} Paired chromosomes must separate with perfect fidelity, so that each gamete receives exactly one copy of every chromosome.^{85,86} Get it right: the cell divides cleanly. Get it wrong — homologous chromosomes stick together, or sister chromatids refuse to part — and one daughter cell receives an extra chromosome while the other receives none. This is nondisjunction.⁸⁵ And its consequences, once a defective gamete is fertilized, echo through every cell of the resulting organism.⁸⁵

Autosomal trisomies — three copies of an autosome — are generally devastating, because autosomes are densely packed with dosage-sensitive genes.^{87,88} Most autosomal trisomies are incompatible with life and end in miscarriage.⁸⁸ The survivors are the exceptions. Trisomy 21, the most viable, occurs in approximately **1 in 660 live births** — a testament to chromosome 21's relative gene poverty.⁸⁹ Trisomies 18 and 13 are far more severe; most affected infants survive only days to weeks.⁹⁰

Sex chromosome aneuploidies are generally better tolerated.⁹¹ The X chromosome's inactivation mechanism — whereby all but one X chromosome is silenced in every cell⁹² — buffers the gene dosage effect. Turner syndrome (45, X) stands as a biological curiosity: the only monosomy compatible with live birth in humans, because monosomy for any autosome is invariably lethal.⁹³ The Y chromosome, gene-poor and largely devoted to male sex determination, contributes little dosage sensitivity.^{93,94}



IS RACE A GENETIC CATEGORY?

DEBUNKING A MYTH

Few misconceptions carry heavier consequences than the belief that human racial categories — as commonly understood socially and politically — correspond to meaningful genetic groupings. This claim has been used to justify discrimination, eugenics, and worse.⁹⁵ It deserves a clear, unambiguous, scientifically grounded response.

Human beings are, as a species, remarkably genetically similar to one another. The total genetic diversity within our species is less than that found within a single troop of wild chimpanzees.⁹⁶ Any two humans chosen at random from opposite sides of the globe share approximately 99.9% of their DNA sequence.⁹⁷ The 0.1% that varies is the raw material of human genetic diversity — and its distribution is not neatly parcelled into the racial groups that social convention recognises.

The geneticist Richard Lewontin demonstrated in 1972 — and subsequent, far larger studies have confirmed — that approximately 85% of all human genetic variation occurs within traditionally defined racial groups, not between them.⁹⁸ This means that a randomly chosen pair of individuals from the same racial group will, on average, differ genetically almost as much as a pair drawn from two different racial groups on opposite sides of the planet.

This does not mean that ancestry is clinically irrelevant. Certain genetic variants are more prevalent in some ancestral populations than others. Haemoglobin S (sickle cell) is more common in populations with ancestry from malaria-endemic regions.⁹⁹ BRCA1 founder mutations are more common in Ashkenazi Jewish populations.¹⁰⁰

WHAT DATA ACTUALLY SHOWS

- ▶ Human populations cluster genetically — but the clusters reflect patterns of migration, isolation, and admixture over thousands of years, not the social categories of race as historically used in Western medicine and science
- ▶ There is more genetic variation within continental population groups than between them
- ▶ Allele frequencies for clinically relevant variants differ between ancestral populations — but no variant is exclusive to any "race," and frequency differences are matters of degree, not kind
- ▶ Genetic ancestry (proportion of DNA tracing to specific ancestral populations) is distinct from, and often inconsistent with, self-identified racial identity or appearance-based classification

Certain pharmacogenomic variants affecting drug metabolism differ in frequency across ancestral groups.¹⁰¹ These differences are medically meaningful and should inform clinical care.

A key distinction is that ancestral population is a genetic and geographic concept with real biological correlates. In contrast, race is a social and political category with historically contingent, culturally variable boundaries, and it poorly predicts genetic ancestry at the individual level.¹⁰²

The responsible use of genetics in medicine requires acknowledging both of these truths simultaneously: that population-level allele frequency differences exist and matter clinically, and that these differences do not map cleanly onto the racial categories that have been used, and misused, throughout history.

Mendelian vs. Non-Mendelian Inheritance

Classical Mendelian inheritance follows predictable single-gene patterns first described by Gregor Mendel in 1865 and rediscovered in the early twentieth century. Four canonical patterns underlie thousands of rare genetic conditions.

In 1865, a quiet Augustinian friar in Brno, Moravia, presented the results of eight years' work on pea plants to his local natural history society. Gregor Mendel's audience was polite but unimpressed. His paper was cited just a handful of times in the following thirty-five years. Then, in 1900, three biologists independently rediscovered his work. The age of genetics had begun. Mendel's laws — the rules by which traits pass from parents to offspring — have since underpinned the diagnosis and counselling of thousands of inherited conditions.¹⁰³

Autosomal Dominant (AD)

One mutant allele is sufficient to cause disease.¹⁰⁴ An affected parent has a 50% chance per pregnancy of passing the condition on. Male-to-male transmission is possible (distinguishing it from X-linked patterns).¹⁰⁴ Variable expressivity is common — the same mutation can produce dramatically different severity in different family members. Classic examples: Marfan syndrome (FBN1), neurofibromatosis type 1 (NF1), Huntington's disease.¹⁰⁴

Autosomal Recessive (AR)

Both copies of a gene must be mutant for disease to manifest.¹⁰⁵ Carrier parents — each carrying one silent mutant allele — face a 25% risk with each pregnancy.¹⁰⁵ The condition often appears suddenly, in a family with no prior history. It is especially common in consanguineous families or populations with a founder effect.^{105,106} Classic examples: cystic fibrosis, PKU, sickle cell disease.¹⁰⁶

X-Linked Recessive

The mutant gene lives on the X chromosome. Males, with only one X, are fully exposed; females, with two X chromosomes, are usually protected by a normal allele on the second X.¹⁰⁷ Carrier mothers have a 50% chance of transmitting the condition to each son.¹⁰⁷ Critically, there is no male-to-male transmission — a son receives his father's Y chromosome, not his X. Classic examples: Duchenne muscular dystrophy (DMD), Fragile X syndrome, haemophilia A.^{107,108}

NON-MENDELIAN PATTERNS

Genomic Imprinting

Some genes wear a chemical label that records which parent contributed them. At the 15q11-q13 locus, paternal genes are normally expressed and maternal genes silenced — or vice versa, depending on the gene.⁴⁶ Disrupt the paternal contribution and you get Prader-Willi syndrome.¹⁰⁹ Disrupt the maternal contribution and you get Angelman syndrome.¹⁰⁹ Same region. Opposite parents. Completely different diseases.

Uniparental Disomy (UPD)

Occasionally, both copies of a chromosome are inherited from the same parent — neither mutation nor deletion, yet disease results anyway.^{110,111} When the duplicated chromosome carries an imprinted region, the normal balance of expressed and silenced genes is thrown off.^{110,111}

Anticipation

In trinucleotide repeat disorders, the mutation grows with each generation.^{78,112} A grandparent may carry a borderline expansion and be mildly affected or unaware; their child carries a larger expansion and develops symptoms in midlife; their grandchild carries a still-larger expansion and presents in childhood.^{78,112} The disease accelerates down the family tree.¹¹²

Mitochondrial Inheritance

All mitochondria derive from the oocyte — therefore mtDNA disorders are maternally inherited.^{113,114} Severity depends on heteroplasmy levels and tissue threshold.^{113,114}

Multifactorial / Polygenic

Most common diseases (type 2 diabetes, heart disease, schizophrenia) arise from the interaction of many genetic variants with environmental factors.¹¹⁵ No simple Mendelian pattern.

Mitochondrial Genetics and Energy Disorders

Inside almost every cell in your body — tucked within the cytoplasm, outside the nucleus — are hundreds of tiny structures, each with their own genome. Mitochondria are ancient bacteria that, roughly two billion years ago, were engulfed by a proto-eukaryotic cell. They never left. Today, they are our cells' power plants, generating the ATP that keeps every cellular process running. And they carry, still, a remnant of their bacterial ancestry: *their own circular DNA*.

The human mitochondrial genome is compact — just 16,569 base pairs — but essential.¹¹⁶ It encodes 13 subunits of the oxidative phosphorylation machinery, 22 transfer RNAs, and 2 ribosomal RNAs.^{116,117} Lose the function of any of these, and the cell's ability to generate energy collapses. Since the tissues most vulnerable are those with the highest energy demands — brain, muscle, heart, kidney — mitochondrial diseases tend to strike with particular cruelty at the organs least able to compensate.

The clinical picture is further complicated by **heteroplasmy** — the coexistence, within a single cell, of mutant and wild-type mitochondrial DNA molecules.¹¹⁸ A cell may harbour 500 mitochondria, of which 200 carry a mutation. Whether disease manifests depends on the proportion of mutant molecules — and that proportion can shift stochastically as cells divide and mitochondria are randomly distributed between daughter cells.^{116,117} This is why mitochondrial diseases can appear different even between tissues of the same individual.

MITOCHONDRIAL GENOME: KEY FACTS

16,569 bp

circular double-stranded mtDNA

13 proteins encoded

alloxidativephosphorylation subunits

22 tRNAs + 2 rRNAs

encoded entirely in mtDNA

Maternal inheritance

allmitochondriafromoocyte only

Polyploidy

hundredsto thousands copies per cell

Heteroplasmy

mixedwild-type / mutant populations

Threshold effect

~60–90%mutant load required for disease

Well, hello.

Introducing a new discount for
Genomics Today members.

GENSURE is known for
saving people money on
car insurance.


And now, as a Genomics
Today member, you may
qualify for a special new
discount on GENSURE
insurance.

Simply get a quote today
and mention your
affiliation. In just 15
minutes, you can see how
much you could save.

Get a free quote.

GENSURE®
gensure.com





A significant proportion of pancreatic cancers are linked to inherited genetic mutations—especially in the BRCA2 gene (and less commonly BRCA1).^{12,13} These genes normally help repair damaged DNA, but when they're mutated, DNA errors can accumulate, increasing cancer risk.

Trinucleotide Repeat Expansion: When DNA Forgets to Stop

Every time a cell divides, its DNA replication machinery faces a peculiar problem. Short tandem repeat sequences — the same three letters, repeated over and over in a row — are difficult to copy faithfully. The replication machinery can *slip* as it moves along the repeat, losing track of its place, adding extra copies. Most of the time, repair mechanisms catch the error. But in certain genes, in certain people, the slippage goes uncorrected — and the repeat grows. Copy by copy. Generation by generation. Until, finally, it crosses a threshold — and the disease begins.

This is the biology of trinucleotide repeat expansion disorders: a family of conditions united by a single mechanism, but manifesting in wildly different ways depending on where in the genome the expansion occurs.^{78,112} CAG repeats within a coding sequence, as in Huntington's disease, produce a protein laced with extra glutamine residues — a toxic stretch that misfolds and aggregates inside neurons.¹¹ CGG repeats in the promoter region of FMR1, as in Fragile X syndrome, trigger methylation-based silencing of the gene entirely.¹¹⁹ CTG repeats in the 3' region of DMPK sequester RNA-binding proteins, disrupting the splicing of dozens of downstream genes.¹²⁰ Same basic mechanism. Completely different molecular consequences.

The phenomenon of **genetic anticipation** — by which the disease strikes earlier and more severely in successive generations — is one of the most haunting in all of medicine.^{112,121} A grandmother carries 40 CGG repeats in FMR1: she is a carrier, intellectually normal. Her daughter inherits 90 repeats: still a carrier, still normal, but beginning to accumulate risk. Her grandson inherits 250 repeats: the full mutation, fully methylated, FMR1 silenced, FMRP absent. He will have Fragile X syndrome. The disease grew, unseen, across three generations.



EpiDermix

Skincare like
never before.

THE NEWEST IN VEGAN BEAUTY.
YOUR SKIN'S BEST FRIEND.

CELL-EBRATE BETTER SKIN



§

TECHNIQUES


Karyotyping, FISH, microarray, PCR, sequencing, and cancer genomics — the diagnostic toolkit of the modern clinical geneticist.

Karyotyping: Seeing Chromosomes in Action


For most of the twentieth century, if you wanted to see a person's chromosomes — truly see them — there was only one way to do it. You would take a blood sample, coax the cells to divide in culture, arrest them at metaphase with a poison that froze the spindle, swell them with hypotonic salt solution until the chromosomes spread apart, fix them to a glass slide, and stain them with Giemsa. Then you would look down a microscope and, if you knew what you were looking for, the bands of light and dark would tell you a story.¹²² A story, sometimes, of extra chromosomes or missing ones. Of translocations and inversions. Of a life written differently.

Karyotyping remains, sixty years on, an irreplaceable diagnostic tool. A standard karyotype at 400–550 band resolution detects deletions or duplications of approximately 5–10 Mb — large enough to encompass hundreds of genes.¹²³ High-resolution karyotyping extends this to ~3–4 Mb. But its unique power lies elsewhere: karyotyping is the only routine cytogenetic test that can detect balanced chromosomal rearrangements — translocations and inversions that move genetic material without changing the total dosage.^{123,124}

These balanced rearrangements cause no disease in the carrier themselves, but can produce severely unbalanced offspring.¹²³ Array CGH, for all its superior resolution, is blind to them.¹²⁵



G-banded human female chromosomes, obtained with trypsin treatment followed by Giemsa staining.¹²⁶



Male karyotype showing trisomy 21.

Key indications: suspected chromosomal syndrome, recurrent pregnancy loss, infertility, ambiguous genitalia in newborns, structural anomalies on prenatal ultrasound, and haematological malignancies — where specific translocations define tumour subtypes and guide treatment.^{123,124}



Classic Style
20% OFF DISCOUNT

\$70



Modern Style
30% OFF DISCOUNT

\$60

WWW.DOLCEANDGUANINE.COM




FISH: Fluorescent Windows into the Genome

Imagine you could design a molecular probe that would seek out a single, specific sequence among three billion base pairs of tangled DNA — find it, and then glow. That is essentially what FISH does.^{127,128} Fluorescence in situ hybridization uses fluorescently labelled DNA probes that are applied to denatured chromosomal DNA, where they hybridize specifically to their complementary target sequences.^{127,128} Under a fluorescence microscope, the probe lights up — a pinpoint of colour marking a specific chromosomal locus with extraordinary precision.^{127,128}

FISH can be performed on metaphase chromosomes — for maximum positional resolution — or on interphase nuclei, where it can be done without cell culture.^{127,128} This interphase FISH capability transforms it into a rapid diagnostic tool: results within 24–48 hours from uncultured amniotic fluid cells, compared to 1–2 weeks for a full karyotype.^{127,128} In a prenatal context, those extra days can matter enormously to a family.^{127,128}

The probe types are varied and strategically designed. Centromeric probes rapidly count chromosome copies — essential for prenatal aneuploidy screening.¹²⁸ Locus-specific probes illuminate single genomic loci — the tool of choice for microdeletion syndromes: DiGeorge at 22q11, Williams at 7q11, WAGR at 11p13.¹²⁹ Dual-fusion probes span the breakpoints of cancer-associated translocations, revealing the fusion gene as two signals that overlap: a tiny orange-green kiss under the microscope that tells a clinician their patient has Chronic Myeloid Leukemia (CML).^{130,131,132}



MICROARRAY


The Copy-Number Map


In 2010, a consensus statement from major genetics societies announced a quiet revolution: chromosomal microarray analysis (CMA) should replace conventional karyotyping as the first-line diagnostic test for patients with unexplained intellectual disability, developmental delay, autism, or multiple congenital anomalies.¹⁸ This was not a small thing. Karyotyping had been the gold standard for fifty years. But its resolution — measuring in megabases — was simply no longer adequate for a field that had learned to think in kilobases.

Array CGH works by competitive hybridization.¹³³ Patient DNA and reference DNA are labelled with different fluorescent dyes — red and green — and mixed in equal quantities.¹³³ Both are applied to an array spotted with tens of thousands of DNA probes spread across the genome. Where the patient has two copies of a region, the red and green signals balance: the ratio is 1.^{133,134}


Where the patient has a deletion (one copy), the patient signal is weaker: ratio 0.5. Where there is a duplication (three copies), the patient signal dominates: ratio 1.5. The result is a genomic copy-number map, plotted across every chromosome, at kilobase resolution.^{17,133,134}

SNP arrays add a further dimension: genotyping at each probe position. This allows detection of regions of homozygosity¹³⁵ — long stretches where both alleles are identical — which can indicate consanguinity, or, crucially, uniparental disomy. The great challenge of CMA is not technical but interpretive: distinguishing pathogenic copy number variants from the benign polymorphisms that pepper every normal genome.¹³⁶ This requires comparison against population databases — the Database of Genomic Variants (DGV) — and careful clinical correlation. The variant itself is only part of the answer.





Pancreatic desmoplasia is driven in part by tumor-secreted signals—often downstream of KRAS mutations—that activate stromal fibroblasts and trigger dense fibrotic tissue formation around the tumor.¹³⁷



For dominant conditions with reduced penetrance (e.g., BRCA2-associated cancer, some cardiac channelopathies), an allele can be present without causing disease — but it can still be transmitted. Absence of disease in a parent does not guarantee absence of the mutation, and thus does not protect offspring.^{67,68}

PCR & Sequencing:

Sanger vs Next-Generation Sequencing


In the mid-1980s, a chemist named Kary Mullis had an idea during a late-night drive through the mountains of northern California. What if you could copy a specific stretch of DNA — over and over, exponentially — until you had enough to work with? The idea struck him so forcefully that he stopped the car. The technique he conceived that night, the polymerase chain reaction, would transform biology. He would win the Nobel Prize for it in 1993.^{138,139}


PCR works through elegant simplicity: heat DNA to separate its strands (denaturation, ~94°C); cool it so short primer sequences can bind to their specific targets (annealing, ~55–68°C); warm it so DNA polymerase can copy the sequence between the primers (extension, ~72°C).^{140,141} Repeat 25–40 times. A single target sequence, present in vanishing quantities in a drop of blood or a swab of saliva, becomes millions of copies — enough to see, sequence, and analyse.¹⁴⁰ Today, PCR underpins virtually every molecular diagnostic test: mutation detection, repeat sizing, methylation analysis, quantitative monitoring of cancer treatment response.¹⁴¹

Sanger sequencing — the dideoxy chain-termination method — provided the first means of reading those amplified sequences. Reading ~700–1000 bp per reaction with near-perfect accuracy, it remains the gold standard for confirming specific variants. But it is slow and expensive for large-scale work.¹⁴²

Next-generation sequencing (NGS) changed everything: millions of DNA fragments sequenced simultaneously, their reads assembled computationally into a complete genomic picture. Whole-exome sequencing queries every protein-coding exon in the genome.¹⁴³

Whole-genome sequencing reads it all. The cost of sequencing a human genome has fallen from \$3 billion in 2003 to under \$1,000 today — one of the steepest price declines in the history of technology.¹⁴⁴






Cancer Genomics

Mutations that Drive Tumors

A cancer cell is, in the most literal sense, a mutant. It is a cell that has accumulated enough genetic changes — in oncogenes, in tumour suppressors, in DNA repair genes — to escape the controls that normally govern growth, differentiation, and death. Cancer is not one disease. It is hundreds of diseases, each defined by its own constellation of mutations, each requiring its own therapeutic strategy. And understanding those mutations — reading the genome of a tumour — is now central to treating it.

Chromosomal rearrangements are the hallmark of haematological malignancies.¹⁴⁵ The Philadelphia chromosome — a reciprocal translocation⁷ between chromosomes 9 and 22, $t(9;22)(q34;q11.2)$ — was the first cancer-associated chromosomal abnormality ever identified, discovered in Philadelphia in 1960.^{146,147} It creates a fusion gene, BCR-ABL1, encoding a constitutively active tyrosine kinase that drives the uncontrolled proliferation of myeloid cells in chronic myeloid leukaemia (CML).¹⁴⁶ The kinase never stops firing. The cells never stop dividing.¹⁴⁶

The development of imatinib (Gleevec) — a small molecule designed specifically to inhibit the BCR-ABL1 kinase — transformed CML from a disease with a median survival of 3–6 years into a manageable chronic condition.¹⁴⁸ It was one of the first demonstrations that a cancer driver mutation could be targeted with a drug designed, from first principles, to block it.¹⁴⁸ It remains one of the most celebrated achievements in modern oncology. The model — sequence the tumour, identify the driver, design the drug — has since been applied across dozens of cancer types.





CASE STUDIES

Five landmark conditions that illustrate the principles of molecular genetics and cytogenomics in clinical practice — from diagnosis to therapy.



Wilms' tumour is often associated with mutations in the WT1 gene, which plays a key role in kidney development.¹⁴⁹


WAGR Syndrome

The Story of 11p13


A newborn is examined. The iris is missing, not pale or damaged, but absent, leaving an unbroken dark circle where the coloured ring should be. **Aniridia**, the ophthalmologist notes, a rare finding. But geneticists know that aniridia, when congenital and bilateral, is rarely an isolated finding. And so the search begins for what else may lie beneath the surface.

WAGR syndrome takes its name from its four cardinal features: Wilms tumour, aniridia, genitourinary anomalies, and intellectual disability.¹⁵⁰ It is a contiguous gene deletion syndrome — meaning that its varied manifestations arise not from mutations in a single gene, but from the simultaneous haploinsufficiency of multiple adjacent genes deleted from chromosome band 11p13.¹⁵⁰

Two genes are critical. **PAX6**, a master regulator of eye development, is expressed from a single copy in WAGR patients — and one copy is not enough.^{150,151} The iris fails to form. **WT1**, a tumour suppressor gene, is also present in only one copy — and that single surviving copy may, in approximately 50% of cases, be somatically inactivated in a developing kidney cell.¹⁵¹ The result is Wilms tumour: a childhood renal malignancy that, caught early, is highly treatable.¹⁵¹ This is why WAGR children require renal ultrasound surveillance every three months until the age of eight.¹⁵¹ Not as a precaution. As a near-certainty.



Most WAGR cases arise de novo — appearing with no family history, from a new deletion in a parental germ cell.¹⁵² Parental karyotyping is nevertheless recommended, to exclude the rare possibility of a balanced translocation or gonadal mosaicism that could affect recurrence risk.¹⁵² The deletion itself — typically 1–20 Mb — is detectable by FISH using PAX6/WT1 probes, or by chromosomal microarray.¹⁵¹




Cystic Fibrosis and CFTR $\Delta F508$

For most of the twentieth century, a diagnosis of cystic fibrosis was, in essence, a countdown. A child born with CF in the 1960s might expect to live a decade.⁵⁷ By the 1980s, survival into the twenties was becoming possible. Today, in the era of CFTR modulators, people born with CF can reasonably expect to live into their sixties and beyond. This is one of the most remarkable therapeutic transformations in the history of rare disease — and it begins with three missing base pairs.

Cystic fibrosis is the most common lethal autosomal recessive disorder in Northern European populations, affecting approximately 1 in 2,500–3,500 live births.^{76,153} It results from mutations in CFTR — the cystic fibrosis transmembrane conductance regulator, an ATP-gated chloride channel expressed on the surface of epithelial cells throughout the body.^{57,76,153} Without properly functioning CFTR, chloride transport fails, water doesn't follow, and secretions thicken. In the lungs, the airways become clogged with mucus that bacteria colonize with grim efficiency.¹⁵³ In the pancreas, the exocrine ducts block and the gland digests itself. In the reproductive tract, the vas deferens fails to form.¹⁵³

The villain, in ~70% of Northern European CF cases, is $\Delta F508$ (officially p.Phe508del): a 3-bp in-frame deletion that removes the phenylalanine at position 508 of the CFTR protein.^{76,153} This single missing amino acid causes the newly synthesized CFTR to misfold in the endoplasmic reticulum.¹⁵³ The cell's quality-control machinery flags it as defective and degrades it before it ever reaches the cell surface.¹⁵³ The channel that should be there is simply... absent.

The development of CFTR modulators — small molecules that reach into the misfolded protein and correct it — represents a triumph of structure-based drug design. The triple combination elexacaftor/tezacaftor/ivacaftor (ETI, marketed as Trikafta or Kaftrio) corrects the trafficking defect, stabilises the protein, and then potentiates its channel opening.²⁶ Clinical trials showed improvement in FEV1 of approximately 14%, a transformation in quality of life, and — perhaps most significantly — a future that could be planned.¹⁵⁴




CFTR MUTATION CLASSES

- Class I — No protein**
premature stop codon (e.g., G542X)
- Class II — Misfolding/degradation**
 $\Delta F508$ (most common)
- Class III — Gating defect**
G551D (ivacaftor-responsive)
- Class IV — Reduced conductance**
R117H (milder phenotype)
- Class V — Reduced synthesis**
splice-site mutations
- Class VI — Reduced stability**
truncating C-terminal mutations

Huntington's Disease:

CAG Repeats and Neurodegeneration



There is something especially cruel about Huntington's disease. It is cruel in the timing — striking in midlife, when careers are established, families are raised, futures are planned. It is cruel in the mechanism — a protein corrupted by its own extra length, toxic to the very neurons it inhabits, slowly dismantling the circuits of movement, cognition, and personality. And it is cruel in the knowledge, because the genetic test is definitive.^{59,155} A positive result is not a risk. It is a certainty.

Huntington's disease is caused by expansion of a CAG trinucleotide repeat in the HTT gene on chromosome 4p16.3.^{59,155} Normally, this region contains 10–35 CAG repeats, encoding a correspondingly short polyglutamine tract in the huntingtin protein.⁵⁹ Above 40 repeats, the protein misfolds — accumulating in neuronal intranuclear inclusions and eventually causing the selective degeneration of medium spiny neurons in the striatum, particularly the caudate nucleus and putamen.⁵⁹ The motor, cognitive, and psychiatric symptoms follow with near-inevitability.



Onset is typically in midlife (35–50 years), with a triad of motor dysfunction (chorea — those characteristic involuntary dancing movements — rigidity, and bradykinesia), cognitive decline progressing to dementia, and psychiatric manifestations (depression, irritability, psychosis).^{59,155} Juvenile Huntington's, where the expansion exceeds 60 repeats, presents before age 20, with rigidity rather than chorea as the predominant feature, and progresses more rapidly.¹⁵⁶ Mean survival from symptom onset is 15–20 years.¹⁵⁶

Presymptomatic genetic testing — available to at-risk individuals before any symptoms appear — is one of the most ethically complex situations in clinical genetics.¹⁵⁷ A positive result, in a person who may not develop symptoms for two or three decades, carries enormous psychological weight.^{157,158} International guidelines mandate comprehensive pre- and post-test counselling by an experienced multidisciplinary team. Many at-risk individuals choose not to know. That choice, too, must be respected.

Fragile X Syndrome and FMR1 Silencing

It is called "fragile" because of what happens to the X chromosome under certain laboratory conditions: a narrow constriction appears near the tip of the long arm, as if the chromosome is about to break.¹⁵⁹ But the fragility is an illusion — a quirk of the old tissue culture conditions that revealed it. The real story is happening at the molecular level, and it is a story of a gene silenced by its own expansion: a sequence that, having grown too long, triggers a cellular response that shuts it down permanently.¹⁶⁰

Fragile X syndrome is caused by the expansion of a CGG trinucleotide repeat in the 5' untranslated region of the FMR1 gene on the X chromosome (Xq27.3).^{160,162} In a normal allele, this repeat runs 6–44 copies — present, but inert. In a premutation allele (55–200 repeats), the repeat is extended but FMR1 is still transcribed, albeit with difficulty.¹⁶⁰ Premutation carriers produce elevated FMR1 mRNA that can be toxic in neurons.^{160,162} This causes the late-onset tremor and ataxia syndrome FXTAS in older males, and primary ovarian insufficiency (FXPOI) in approximately 20% of female carriers.^{160,162} In a full mutation allele (>200 repeats), the expanded CGG sequence triggers dense CpG methylation of the FMR1 promoter.^{160,162} The gene is silenced. The FMRP protein — an RNA-binding protein essential for synaptic plasticity and the maturation of dendritic spines — is absent.¹⁶³



The consequences are profound. Males with the full mutation present with moderate to severe intellectual disability, macroorchidism (enlarged testes, a post-pubertal finding), an elongated face, large ears, hyperactivity, and, in many cases, autism spectrum features.¹⁶⁰ The autism connection is not coincidental: FMRP normally acts as a brake on protein synthesis at synapses, and its loss leads to excessive, unregulated synaptic signalling — a state that overlaps mechanistically with other forms of autism.^{160,162} Females with the full mutation are protected, to varying degrees, by the normal FMR1 allele on their second X chromosome — though many still show cognitive and behavioural involvement.¹⁶⁰

The Philadelphia Chromosome


and the Birth of Targeted Therapy

In 1960, two pathologists at the University of Pennsylvania — Peter Nowell and David Hungerford — peered down their microscopes at the cells of patients with chronic myeloid leukaemia and noticed something strange.¹⁶⁴ One chromosome was shorter than it should be.¹⁶⁴ Consistently. In every CML patient they examined. They called it the Philadelphia chromosome, after the city where they worked.¹⁶⁴ They had no idea, at the time, that they were looking at the first cancer-associated chromosomal abnormality ever identified — or that it would, fifty years later, point the way to one of medicine's greatest therapeutic triumphs.

The Philadelphia chromosome arises from a reciprocal translocation: t(9;22)(q34;q11.2).⁷ A stretch of chromosome 9, carrying the ABL1 tyrosine kinase gene, breaks off and attaches to chromosome 22, where it fuses with the BCR gene.¹⁶⁵ The resulting chimeric **BCR-ABL1** fusion gene encodes a protein that has lost the normal regulatory switches that keep ABL1 kinase activity under control.^{146,165} The kinase is permanently switched on — signalling relentlessly through RAS, PI3K/AKT, and STAT5 — driving myeloid cells to proliferate without stopping.¹⁶⁶

For four decades after its discovery, CML was managed with chemotherapy and bone marrow transplantation, with a median survival of 3–6 years. Then, in the late 1990s, a chemist named Brian Druker had an idea: what if you could design a small molecule that would fit precisely into the ATP-binding pocket of the BCR-ABL1 kinase, blocking it completely?¹⁶⁷ The molecule he developed — imatinib, marketed as Gleevec — did exactly that.¹⁶⁸ In clinical trials, it produced complete cytogenetic responses in the great majority of patients.¹⁶⁸ The leukemia cells died. The normal cells lived. Survival curves transformed almost overnight.

Imatinib remains, twenty-five years later, a paradigm of rational drug design: start with a molecular target, understand its structure, design the inhibitor. Second- and third-generation TKIs (dasatinib, nilotinib, ponatinib) have extended this approach to patients who develop resistance through mutations in the ABL1 kinase domain.¹⁶⁹ Today, many patients achieve deep molecular responses — BCR-ABL1 transcripts undetectable by PCR — and some can even discontinue therapy, remaining in treatment-free remission indefinitely.





REFERENCE

Short notes on key concepts, a comprehensive glossary, and curated further reading.

SHORT NOTES

Essential Concepts at a Glance

Haploinsufficiency Explained

Haploinsufficiency occurs when a single functional copy of a gene is insufficient to maintain normal function — even with the other allele present. It underlies many autosomal dominant disorders: PAX6 haploinsufficiency causes aniridia in WAGR syndrome.¹²⁹ Whether a gene is haploinsufficient depends on how tightly its pathway is regulated and whether rate-limiting steps exist. Many genes tolerate loss of one allele (haplosufficiency).

Genomic Imprinting: PWS vs Angelman Syndrome

Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are caused by loss of function at the same 15q11–q13 region but from different parental chromosomes — illustrating the profound effects of genomic imprinting.^{46,109} In PWS, the paternally inherited chromosome 15 region is absent or silenced (deletion, maternal UPD15, or imprinting center defect), causing hypotonia, hyperphagia, hypogonadism, and mild ID.¹⁰⁹ In AS, the maternally inherited UBE3A allele is lost, causing severe ID, absent speech, seizures, and inappropriate laughter.¹⁰⁹ Both are detectable by methylation-specific PCR or FISH.

Why Mosaicism Matters

Mosaicism — the presence of two or more genetically distinct cell lines originating from a single zygote — arises from postzygotic mutation. The timing of the event determines the proportion and distribution of affected cells. Somatic mosaicism produces attenuated clinical features (e.g., mosaic trisomy 21 with milder Down syndrome features).⁸⁹ Gonadal mosaicism is clinically critical: a phenotypically normal parent with germ-cell mosaicism for a dominant mutation (e.g., DMD, OI) can have multiple affected children, mimicking autosomal recessive inheritance.⁸⁹

Somatic vs Germline Mutations

Germline mutations occur in germ cells (eggs or sperm) and are transmitted to offspring — present in every cell of the body from conception. They underlie inherited genetic disorders and are detected in standard genetic testing of blood or saliva. Somatic mutations arise in non-germ cells after fertilization — confined to a tissue or clone of cells, and not transmitted to offspring. Every tumor carries its own somatic mutational landscape. Somatic mutations can also cause mosaic Mendelian disorders (e.g., mosaic NF1), and are the basis of all cancer.

REFERENCE

Glossary of Genetic Terms

Allele

One of two or more alternative forms of a gene at a given locus on a chromosome.

Array CGH

Chromosomal microarray analysis comparing patient DNA copy number against a reference genome across hundreds of thousands of loci simultaneously.

Autosomal dominant (AD)

Inheritance pattern where one mutant allele is sufficient to cause disease; 50% of offspring of an affected individual are at risk.

CNV (Copy Number Variant)

A segment of DNA ≥ 1 kbp present in a variable number of copies relative to a reference genome; may be pathogenic or benign.

Compound heterozygote

An individual with two different mutant alleles at the same locus (e.g., two different CF mutations), causing autosomal recessive disease.

Deletion

Loss of a segment of chromosomal DNA, ranging from a single nucleotide to an entire chromosome arm.

Epigenetics

Heritable changes in gene expression that do not involve alterations in the DNA sequence; includes DNA methylation, histone modification, and noncoding RNA pathways.

Frameshift mutation

An insertion or deletion of nucleotides not in multiples of three, shifting the reading frame and altering all downstream amino acids, typically producing a nonfunctional protein.

Aneuploidy

An abnormal chromosome number — either gain (trisomy) or loss (monosomy) of one or more chromosomes.

Anticipation

The phenomenon in which disease onset occurs earlier and/or severity increases in successive generations, classically caused by trinucleotide repeat expansion.

Autosomal recessive (AR)

Inheritance requiring two mutant alleles; carriers (one mutant allele) are typically unaffected. Carrier $\times$ carrier: 25% affected offspring risk.

Centromere

The constricted region of a chromosome where the kinetochore assembles for microtubule attachment during mitosis and meiosis. Essential for chromosome segregation.

De novo mutation

A new mutation not inherited from either parent; arises spontaneously in a germ cell or very early embryogenesis. Recurrence risk is generally low but not zero (gonadal mosaicism).

DNA methylation

Addition of a methyl group to cytosine at CpG dinucleotides; typically associated with transcriptional repression of nearby genes.

FISH

Fluorescence in situ hybridization — a cytogenetic technique using fluorescently labeled DNA probes to detect and localize specific DNA sequences on chromosomes.

G-banding

Chromosome staining technique using Giemsa dye after mild protease treatment, producing characteristic light (gene-rich, R-band equivalent) and dark (gene-poor) bands.

GLOSSARY — CONTINUED

Genomic imprinting

An epigenetic phenomenon where gene expression depends on parental origin; only the maternally or paternally inherited allele is expressed at imprinted loci.

Heterozygous

Possessing two different alleles at a given locus on homologous chromosomes.

Homozygous

Possessing two identical alleles at a given locus.

Intron

A non-coding sequence within a gene that is transcribed into pre-mRNA but spliced out before translation.

Karyotype

An organized display of an individual's chromosomes, arranged by size and banding pattern, used to detect numerical and structural abnormalities.

Mendelian inheritance

Patterns of inheritance for single-gene traits: autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive.

Mitochondrial DNA (mtDNA)

The ~16.6 kb circular genome within mitochondria; maternally inherited; encodes 13 oxidative phosphorylation subunits, 22 tRNAs, 2 rRNAs.

Nonsense mutation

A nucleotide substitution creating a premature stop codon, typically resulting in a truncated, nonfunctional protein subject to nonsense-mediated decay.

Phenotype

The observable characteristics of an individual resulting from the interaction of genotype and environment.

Premutation

An allele with an intermediate number of trinucleotide repeats (e.g., 55–200 CGG in FMR1) that is phenotypically mild but prone to expansion in offspring.

SNP (Single Nucleotide Polymorphism)

A common variation at a single nucleotide position; used as genetic markers in association studies and SNP microarrays.

Telomere

Repetitive DNA sequences (TTAGGG repeats) capping chromosome ends; protect chromosomal integrity and shorten with each cell division.

Haploinsufficiency

A condition where a single functional copy of a gene is insufficient for normal function; underlies many autosomal dominant disorders.

Heteroplasmy

The presence of a mixture of wild-type and mutant mitochondrial DNA molecules within a cell or organism. Severity of mitochondrial disease correlates with mutant load.

Imprinting center

A genomic region that controls the establishment and maintenance of epigenetic imprints across an imprinted domain.

Locus

The specific chromosomal location of a gene or DNA sequence.

Loss of heterozygosity (LOH)

The somatic loss of one allele at a locus, often unmasking a recessive tumor suppressor mutation; key event in Knudson's two-hit model of cancer.

Missense mutation

A nucleotide substitution that changes one amino acid to another in the encoded protein.

Mosaicism

The presence of two or more genetically distinct cell populations within a single individual, arising from postzygotic mutation.

Penetrance

The proportion of individuals with a given genotype who manifest the associated phenotype. Complete penetrance = 100%; reduced penetrance = <100%.

Polymorphism

A genetic variant present in ≥1% of the population; may be benign (SNP) or contribute to disease susceptibility.

Proband

The first affected individual in a family to come to medical attention; also called the index case.

Splice site mutation

A mutation at the conserved intron–exon boundary disrupting normal pre-mRNA splicing, causing exon skipping or intron retention.

REFERENCE

References

1. Watson JD, Crick FHC. Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid. *Nature*. 1953 Apr;171(4356):737–8. doi:[10.1038/171737a0](https://doi.org/10.1038/171737a0)
2. Harper PS. The discovery of the human chromosome number in Lund, 1955–1956. *Hum Genet*. 2006 Mar;119(1–2):226–32. doi:[10.1007/s00439-005-0121-x](https://doi.org/10.1007/s00439-005-0121-x) PubMed PMID: 16463025.
3. Bertini I, Raimondi C. Jérôme Lejeune (1926–1994): A Pioneer in Uncovering the Connection Between Congenital Conditions and Chromosomal Anomalies. *Cureus*. 16(12):e75643. doi:[10.7759/cureus.75643](https://doi.org/10.7759/cureus.75643) PubMed PMID: 39803141; PubMed Central PMCID: PMC11725334.
4. Maguin P, Marraffini LA. From the discovery of DNA to current tools for DNA editing. *J Exp Med*. 2021 Mar 12;218(4):e20201791. doi:[10.1084/jem.20201791](https://doi.org/10.1084/jem.20201791) PubMed PMID: 33710258; PubMed Central PMCID: PMC7961593.
5. Chandra HS, Heistekamp NC, Hungerford A, Morrisette JJD, Nowell PC, Rowley JD, et al. Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome. *Cancer Genet*. 2011 Apr;204(4):171–9. doi:[10.1016/j.cancergen.2011.03.002](https://doi.org/10.1016/j.cancergen.2011.03.002) PubMed PMID: 21536234; PubMed Central PMCID: PMC3092778.
6. Sands B, Brent R. Overview of post Cohen-Boyer methods for single segment cloning and for multisegment DNA assembly. *Curr Protoc Mol Biol*. 2016 Jan;113:3.26.1–3.26.20. doi:[10.1002/0471142727.mb0326s113](https://doi.org/10.1002/0471142727.mb0326s113) PubMed PMID: 27152131; PubMed Central PMCID: PMC4853029.
7. A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining | *Nature* [Internet]. [cited 2026 Apr 10]. Available from: <https://www.nature.com/articles/243290a0>
8. Maxam AM, Gilbert W. A New Method for Sequencing DNA. *Proceedings of the National Academy of Sciences of the United States of America*. 1977;74(2):560–4.
9. Sanger F, Air GM, Barrell BG, Brown NL, Coulson AR, Fiddes CA, et al. Nucleotide sequence of bacteriophage phi X174 DNA. *Nature*. 1977 Feb 24;265(5596):687–95. doi:[10.1038/265687a0](https://doi.org/10.1038/265687a0) PubMed PMID: 870828.
10. The Human Genome Project: Past, Present, and Future | *Science* [Internet]. [cited 2026 Apr 10]. Available from: <https://www.science.org/doi/10.1126/science.2181665>
11. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell*. 1993 Mar 26;72(6):971–83. doi:[10.1016/0092-8674\(93\)90585-E](https://doi.org/10.1016/0092-8674(93)90585-E)
12. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science*. 1994 Oct 7;266(5182):66–71. doi:[10.1126/science.7545954](https://doi.org/10.1126/science.7545954) PubMed PMID: 7545954.
13. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. *Science*. 1994 Sep 30;265(5181):2088–90. doi:[10.1126/science.8091231](https://doi.org/10.1126/science.8091231) PubMed PMID: 8091231.
14. Bougie O, Weberpals JJ. Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review. *International Journal of Surgical Oncology*. 2011 Aug 8;2011:374012. doi:[10.1155/2011/374012](https://doi.org/10.1155/2011/374012) PubMed PMID: 22312502.
15. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, et al. Genome Sequencing in Open Microfabricated High Density Picoliter Reactors. *Nature*. 2005 Sep 15;437(7057):376–80. doi:[10.1038/nature03959](https://doi.org/10.1038/nature03959) PubMed PMID: 16056220; PubMed Central PMCID: PMC1464427.

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use. All clinical decisions should be made in consultation with qualified genetics professionals.
© 2026 Genomics Today — Pathology Final Project.

REFERENCE

References

16. History of Illumina Sequencing & Solexa Technology [Internet]. [cited 2026 Apr 10]. Available from: <https://www.illumina.com/science/technology/next-generation-sequencing/illumina-sequencing-history.html>
17. Use of array-based technology in the practice of medical genetics - Genetics in Medicine [Internet]. [cited 2026 Apr 10]. Available from: <https://www.gimjournal.org/article/S1098-3600%2821%2903914-9/fulltext>
18. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital Anomalies. The American Journal of Human Genetics. 2010 May 14;86(5):749–64. doi:10.1016/j.ajhg.2010.04.006 PubMed PMID: 20466091.
19. Whole-exome sequencing identifies recessive WDR62 mutations in severe brain malformations | Nature [Internet]. [cited 2026 Apr 10]. Available from: <https://www.nature.com/articles/nature09327>
20. Application of Whole Exome Sequencing to Identify Disease-Causing Variants in Inherited Human Diseases [Internet]. [cited 2026 Apr 10]. Available from: <https://genominfo.org/journal/view.php?doi=10.5808/GI.2012.10.4.214>
21. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test - Thevenon - 2016 - Clinical Genetics - Wiley Online Library [Internet]. [cited 2026 Apr 10]. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/cge.12732>
22. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science. 2012 Aug 17;337(6096):816–21. doi:10.1126/science.1225829
23. Mardis ER. Anticipating the \$1,000 genome. Genome Biol. 2006;7(7):112. doi:10.1186/gb-2006-7-7-112 PubMed PMID: 17224040; PubMed Central PMCID: PMC1779559.
24. Davies K. The \$1,000 genome: the revolution in DNA sequencing and the new era of personalized medicine. 1st Free Press hardcover ed. New York, NY: Free Press; 2010. 340 p.
25. FDA Approves TRIKAFTATM (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation | Vertex Pharmaceuticals [Internet]. [cited 2026 Apr 10]. Available from: <https://investors.vrtx.com/news-releases/news-release-details/fda-approves-trikafta-elexacaftortezacaftorivacaftor-and>
26. Ridley K, Condren M. Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy. The Journal of Pediatric Pharmacology and Therapeutics. 2020;25(3):192–7. doi:10.5863/1551-6776-25.3.192
27. A Brief Guide to Genomics [Internet]. [cited 2026 Apr 10]. Available from: <https://www.genome.gov/about-genomics/fact-sheets/A-Brief-Guide-to-Genomics>
28. Muller HJ. Our load of mutations. Am J Hum Genet. 1950 Jun;2(2):111–76. PubMed PMID: 14771033; PubMed Central PMCID: PMC1716299.
29. Ohno S. So much “junk” DNA in our genome. Brookhaven Symp Biol. 1972;23:366–70. PubMed PMID: 5065367.
30. Gil R, Latorre A. Factors Behind Junk DNA in Bacteria. Genes (Basel). 2012 Oct 12;3(4):634–50. doi:10.3390/genes3040634 PubMed PMID: 24705080; PubMed Central PMCID: PMC3899985.

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use. All clinical decisions should be made in consultation with qualified genetics professionals.
© 2026 Genomics Today — Pathology Final Project.

REFERENCE

References

31. Alberts B. Molecular biology of the cell. Sixth edition. New York, NY: Garland Science, Taylor and Francis Group; 2015. 1 p.
32. Human Genome Project Fact Sheet [Internet]. [cited 2026 Apr 10]. Available from: <https://www.genome.gov/about-genomics/educational-resources/fact-sheets/human-genome-project>
33. Chromosome Mapping: Idiograms | Learn Science at Scitable [Internet]. [cited 2026 Apr 10]. Available from: <http://www.nature.com/scitable/topicpage/chromosome-mapping-idiograms-302>
34. Fontana GA, Reinert JK, Thomä NH, Rass U. Shepherding DNA ends: Rif1 protects telomeres and chromosome breaks. Microb Cell. 2018 May 17;5(7):327–43. doi:[10.15698/mic2018.07.639](https://doi.org/10.15698/mic2018.07.639) PubMed PMID: 29992129; PubMed Central PMCID: PMC6035837.
35. Vorsanova SG, Yurov YB, Iourov IY. Human interphase chromosomes: a review of available molecular cytogenetic technologies. Mol Cytogenet. 2010 Jan 11;3:1. doi:[10.1186/1755-8166-3-1](https://doi.org/10.1186/1755-8166-3-1) PubMed PMID: 20180947; PubMed Central PMCID: PMC2830939.
36. Carvalho CMB, Lupski JR. Mechanisms underlying structural variant formation in genomic disorders. Nat Rev Genet. 2016 Apr;17(4):224–38. doi:[10.1038/nrg.2015.25](https://doi.org/10.1038/nrg.2015.25) PubMed PMID: 26924765; PubMed Central PMCID: PMC4827625.
37. Emanuel BS. Molecular Mechanisms and Diagnosis of Chromosome 22Q11.2 Rearrangements. Dev Disabil Res Rev. 2008;14(1):11–8. doi:[10.1002/ddrr.3](https://doi.org/10.1002/ddrr.3) PubMed PMID: 18636632; PubMed Central PMCID: PMC2810965.
38. de Jong AE, Hendriks YMC, Kleibeuker JH, de Boer SY, Cats A, Griffioen G, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology. 2006 Mar;130(3):665–71. doi:[10.1053/j.gastro.2005.11.032](https://doi.org/10.1053/j.gastro.2005.11.032) PubMed PMID: 16530507.
39. Ratko TA, Marbella A, Godfrey S, Aronson N. Enzyme-Replacement Therapies for Lysosomal Storage Diseases [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 [cited 2026 Apr 10]. (AHRQ Comparative Effectiveness Technical Briefs). Available from: <http://www.ncbi.nlm.nih.gov/books/NBK117219/> PubMed PMID: 23390670.
40. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010 Jan;31(1):27–36. doi:[10.1093/carcin/bgp220](https://doi.org/10.1093/carcin/bgp220) PubMed PMID: 19752007; PubMed Central PMCID: PMC2802667.
41. Li C jun. DNA Demethylation Pathways: Recent Insights. Genet Epigenet. 2013 Jul 28;5:43–9. doi:[10.4137/GEG.S12143](https://doi.org/10.4137/GEG.S12143) PubMed PMID: 25512706; PubMed Central PMCID: PMC4222334.
42. DNA methylation dynamics in health and disease [Internet]. [cited 2026 Apr 10]. Available from: <https://pubmed.ncbi.nlm.nih.gov/23463312/>
43. Janzen WP, Wigle TJ, Jin J, Frye SV. Epigenetics: Tools and Technologies. Drug Discov Today Technol. 2010;7(1):e59–65. doi:[10.1016/j.ddtec.2010.07.004](https://doi.org/10.1016/j.ddtec.2010.07.004) PubMed PMID: 21243036; PubMed Central PMCID: PMC3018755.
44. Zhang T, Cooper S, Brockdorff N. The interplay of histone modifications – writers that read. EMBO Rep. 2015 Nov;16(11):1467–81. doi:[10.15252/embr.201540945](https://doi.org/10.15252/embr.201540945) PubMed PMID: 26474904; PubMed Central PMCID: PMC4641500.
45. Mayo Clinic [Internet]. [cited 2026 Apr 10]. Research - Human developmental disorders arising from mutations in epigenetic regulator genes. Available from: <https://www.mayo.edu/research/labs/epigenetic-etiology-human-disease/research/human-developmental-disorders-arising-from-mutations-in-epigenetic-regulator-genes>

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use. All clinical decisions should be made in consultation with qualified genetics professionals.

© 2026 Genomics Today – Pathology Final Project.

REFERENCE

References

46. Repetto GM. Genomic imprinting and human chromosome 15. *Biol Res.* 2001;34(2):141–5. doi:[10.4067/s0716-97602001000200020](https://doi.org/10.4067/s0716-97602001000200020) PubMed PMID: 11715207.
47. Malherbe H, Modell B, Blencowe H, Strong K, Aldous C. A review of key terminology and definitions used for birth defects globally. *J Community Genet.* 2023 Jun;14(3):241–62. doi:[10.1007/s12687-023-00642-2](https://doi.org/10.1007/s12687-023-00642-2) PubMed PMID: 37093545; PubMed Central PMCID: PMC10272040.
48. Kritioti E, Theodosiou A, Parpaite T, Alexandrou A, Nicolaou N, Papaevripidou I, et al. Unravelling the genetic causes of multiple malformation syndromes: A whole exome sequencing study of the Cypriot population. *PLoS One.* 2021 Jul 29;16(7):e0253562. doi:[10.1371/journal.pone.0253562](https://doi.org/10.1371/journal.pone.0253562) PubMed PMID: 34324503; PubMed Central PMCID: PMC8320927.
49. Mancuso G, Serventi L, Cocco C, Lai F, Soddu C, Marica M, et al. Whole-Exome Sequencing Identifies Novel Genetic Variants Associated with Unexplained Neurodevelopmental Disorders in Children. *Int J Mol Sci.* 2026 Jan 18;27(2):964. doi:[10.3390/ijms27020964](https://doi.org/10.3390/ijms27020964) PubMed PMID: 41596607; PubMed Central PMCID: PMC12842178.
50. Jo YH, Choi SH, Yoo HW, Kwak MJ, Park KH, Kong J, et al. Clinical use of whole exome sequencing in children with developmental delay/intellectual disability. *Pediatrics & Neonatology.* 2024 Sep 1;65(5):445–50. doi:[10.1016/j.pedneo.2023.05.015](https://doi.org/10.1016/j.pedneo.2023.05.015)
51. Monroe GR, Frederix GW, Savelberg SMC, Vries TI de, Duran KJ, Smagt JJ van der, et al. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. *Genetics in Medicine.* 2016 Sep 1;18(9):949–56. doi:[10.1038/gim.2015.200](https://doi.org/10.1038/gim.2015.200)
52. cancer CCS/ S canadienne du. Canadian Cancer Society [Internet]. 2024 [cited 2026 Apr 10]. Risks for breast cancer. Available from: <https://cancer.ca/en/cancer-information/cancer-types/breast/risks>
53. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease – The Lancet [Internet]. [cited 2026 Apr 10]. Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(01\)06524-2/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(01)06524-2/abstract)
54. Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. *Cancer.* 2009 May 15;115(10):2222–33. doi:[10.1002/cncr.24200](https://doi.org/10.1002/cncr.24200) PubMed PMID: 19241424; PubMed Central PMCID: PMC2771545.
55. Alliance G, Health D of CD of. Single-Gene Disorders. In: *Understanding Genetics: A District of Columbia Guide for Patients and Health Professionals* [Internet]. Genetic Alliance; 2010 [cited 2026 Apr 10]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK132154/>
56. Human Genetic Disorders: Studying Single-Gene (Mendelian) Diseases | Learn Science at Scitable [Internet]. [cited 2026 Apr 10]. Available from: <http://www.nature.com/scitable/topicpage/rare-genetic-disorders-learning-about-genetic-disease-979>
57. The Cystic Fibrosis Gene Is Found | Science [Internet]. [cited 2026 Apr 10]. Available from: <https://www.science.org/doi/10.1126/science.2772644>
58. Polgreen PM, Comellas AP. Clinical Phenotypes of Cystic Fibrosis Carriers. *Annu Rev Med.* 2022 Jan 27;73:563–74. doi:[10.1146/annurev-med-042120-020148](https://doi.org/10.1146/annurev-med-042120-020148) PubMed PMID: 35084992; PubMed Central PMCID: PMC8884701.
59. Ajitkumar A, Lui F, De Jesus O. Huntington Disease. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 Apr 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK559166/> PubMed PMID: 32644592.
60. Huntington Disease | Learn Science at Scitable [Internet]. [cited 2026 Apr 10]. Available from: <http://www.nature.com/scitable/topicpage/huntington-s-disease-the-discovery-of-the-851>

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use. All clinical decisions should be made in consultation with qualified genetics professionals.

© 2026 Genomics Today – Pathology Final Project.

REFERENCE

References

61. Health (US) NI of, Study BSC. Understanding Human Genetic Variation. In: NIH Curriculum Supplement Series [Internet] [Internet]. National Institutes of Health (US); 2007 [cited 2026 Apr 10]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK20363/>
62. Caballero A, Tenesa A, Keightley PD. The Nature of Genetic Variation for Complex Traits Revealed by GWAS and Regional Heritability Mapping Analyses. *Genetics*. 2015 Dec 1;201(4):1601–13. doi:[10.1534/genetics.115.177220](https://doi.org/10.1534/genetics.115.177220)
63. Statistical Power to Detect Genetic (Co)Variance of Complex Traits Using SNP Data in Unrelated Samples | PLOS Genetics [Internet]. [cited 2026 Apr 10]. Available from: <https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1004269>
64. Wainschein P, Jain D, Zheng Z, Cupples LA, Shadyab AH, McKnight B, et al. Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data. *Nat Genet*. 2022 Mar;54(3):263–73. doi:[10.1038/s41588-021-00997-7](https://doi.org/10.1038/s41588-021-00997-7)
65. Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. *Hum Genet*. 2013;132(10):1077–130. doi:[10.1007/s00439-013-1331-2](https://doi.org/10.1007/s00439-013-1331-2) PubMed PMID: 23820649; PubMed Central PMCID: PMC3778950.
66. Zuk O, Hechter E, Sunyaev SR, Lander ES. The mystery of missing heritability: Genetic interactions create phantom heritability. *Proc Natl Acad Sci U S A*. 2012 Jan 24;109(4):1193–8. doi:[10.1073/pnas.1119675109](https://doi.org/10.1073/pnas.1119675109) PubMed PMID: 22223662; PubMed Central PMCID: PMC3268279.
67. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *JAMA*. 2017 Jun 20;317(23):2402–16. doi:[10.1001/jama.2017.7112](https://doi.org/10.1001/jama.2017.7112) PubMed PMID: 28632866.
68. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol*. 2007 Apr 10;25(11):1329–33. doi:[10.1200/JCO.2006.09.1066](https://doi.org/10.1200/JCO.2006.09.1066) PubMed PMID: 17416853; PubMed Central PMCID: PMC2267287.
69. Tan Q, Christiansen L, Thomassen M, Kruse TA, Christensen K. Twins for epigenetic studies of human aging and development. *Ageing Res Rev*. 2013 Jan;12(1):182–7. doi:[10.1016/j.arr.2012.06.004](https://doi.org/10.1016/j.arr.2012.06.004) PubMed PMID: 22750314; PubMed Central PMCID: PMC3509237.
70. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, et al. Epigenetic differences arise during the lifetime of monozygotic twins. *Proc Natl Acad Sci U S A*. 2005 Jul 26;102(30):10604–9. doi:[10.1073/pnas.0500398102](https://doi.org/10.1073/pnas.0500398102) PubMed PMID: 16009939; PubMed Central PMCID: PMC1174919.
71. Korf BR, Irons MB. *Human Genetics and Genomics*. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 2, Genetic Variation; p. 21.
72. Korf BR, Irons MB. *Human Genetics and Genomics*. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 2, Genetic Variation; p. 22.
73. Korf BR, Irons MB. *Human Genetics and Genomics*. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 2, Genetic Variation; p. 24.
74. Pyeritz RE, Korf BR, Grody WW. *Emery and Rimoin's principles and practice of medical genetics and genomics*. 7th ed. London: Academic press; 2019. Chapter 6, Diagnostic Molecular Genetics; p. 173.
75. Thibodeau PH, Richardson JM, Wang W, Millen L, Watson J, Mendoza JL, et al. The Cystic Fibrosis-causing Mutation $\Delta F508$ Affects Multiple Steps in Cystic Fibrosis Transmembrane Conductance Regulator Biogenesis. *J Biol Chem*. 2010 Nov 12;285(46):35825–35. doi:[10.1074/jbc.M110.131623](https://doi.org/10.1074/jbc.M110.131623) PubMed PMID: 20667826; PubMed Central PMCID: PMC2975206.

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use.

All clinical decisions should be made in consultation with qualified genetics professionals.

© 2026 Genomics Today — Pathology Final Project.

REFERENCE

References

76. Mickle JE, Cutting GR. CLINICAL IMPLICATIONS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MUTATIONS. Clinics in Chest Medicine. 1998 Sep 1;19(3):443–58. doi:[10.1016/S0272-5231\(05\)70092-7](https://doi.org/10.1016/S0272-5231(05)70092-7)
77. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 3, Patterns of Inheritance; p. 54–56.
78. Ramakrishnan S, Gupta V. Trinucleotide Repeat Disorders. In: StatPearls [Internet] [Internet]. StatPearls Publishing; 2024 [cited 2026 Apr 10]. Available from: <https://www.ncbi.nlm.nih.gov/sites/books/NBK559254/> PubMed PMID: 32644680.
79. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 2, Genetic Variation; p. 28–29.
80. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 6, Cell Division and Chromosomes; p. 107–111.
81. Bønløkke S, Stougaard M, Blaakær J, Bertelsen J, Andersen K, Fuglsang K, et al. HPV is an essential driver in recurrence of cervical cancer. Pathology – Research and Practice. 2024 Dec 1;264:155672. doi:[10.1016/j.prp.2024.155672](https://doi.org/10.1016/j.prp.2024.155672)
82. Yeo-Teh NSL, Ito Y, Jha S. High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis. Int J Mol Sci. 2018 Jun 8;19(6):1706. doi:[10.3390/ijms19061706](https://doi.org/10.3390/ijms19061706) PubMed PMID: 29890655; PubMed Central PMCID: PMC6032416.
83. Benjamin CL, Ananthaswamy HN. p53 and the Pathogenesis of Skin Cancer. Toxicol Appl Pharmacol. 2007 Nov 1;224(3):241–8. doi:[10.1016/j.taap.2006.12.006](https://doi.org/10.1016/j.taap.2006.12.006) PubMed PMID: 17270229; PubMed Central PMCID: PMC2080850.
84. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124–8. doi:[10.1073/pnas.88.22.10124](https://doi.org/10.1073/pnas.88.22.10124) PubMed PMID: 1946433; PubMed Central PMCID: PMC52880.
85. Lamb NE, Hassold TJ. Nondisjunction – A View from Ringside. New England Journal of Medicine. 2004 Nov 4;351(19):1931–4. doi:[10.1056/NEJMp048118](https://doi.org/10.1056/NEJMp048118)
86. Gottlieb SF, Tupper C, Tegay DH. Genetics, Nondisjunction. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 Apr 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK482240/> PubMed PMID: 29489267.
87. Zhegalova IV, Vasiluev PA, Flyamer IM, Shtompel AS, Glazyrina E, Shilova N, et al. Trisomies Reorganize Human 3D Genome. Int J Mol Sci. 2023 Nov 7;24(22):16044. doi:[10.3390/ijms242216044](https://doi.org/10.3390/ijms242216044) PubMed PMID: 38003233; PubMed Central PMCID: PMC10671006.
88. Kovaleva NV, Cotter PD. Mosaicism for Autosomal Trisomies: A Comprehensive Analysis of 1266 Published Cases Focusing on Maternal Age and Reproductive History. Genes (Basel). 2024 Jun 13;15(6):778. doi:[10.3390/genes15060778](https://doi.org/10.3390/genes15060778) PubMed PMID: 38927714; PubMed Central PMCID: PMC11202781.
89. Pal A, Daley SF. Down Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 Apr 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK526016/> PubMed PMID: 30252272.
90. Meyer RE, Liu G, Gilboa SM, Ethen MK, Aylsworth AS, Powell CM, et al. Survival of Children with Trisomy 13 and Trisomy 18: A Multi-State Population-Based Study. Am J Med Genet A. 2016 Apr;170(4):825–37. doi:[10.1002/ajmg.a.37495](https://doi.org/10.1002/ajmg.a.37495) PubMed PMID: 26663415; PubMed Central PMCID: PMC4898882.

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use.

All clinical decisions should be made in consultation with qualified genetics professionals.

© 2026 Genomics Today – Pathology Final Project.

REFERENCE

References

91. Legue M, Staszewski M, Mastronardo M, Butera G, Dakic A, Raznahan A. Sex chromosome aneuploidy impacts on human gene expression and regulation: a systematic review. *Mol Med*. 2025 Dec 30;32:11. doi:[10.1186/s10020-025-01404-1](https://doi.org/10.1186/s10020-025-01404-1) PubMed PMID: 41469535; PubMed Central PMCID: PMC12859965.
92. Sharma L, Daley SF. Turner Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 Apr 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK554621/> PubMed PMID: 32119508.
93. Sun Z, Fan J, Wang Y. X-Chromosome Inactivation and Related Diseases. *Genet Res (Camb)*. 2022 Mar 27;2022:1391807. doi:[10.1155/2022/1391807](https://doi.org/10.1155/2022/1391807) PubMed PMID: 35387179; PubMed Central PMCID: PMC8977309.
94. Chang SC, Tucker T, Thorogood NP, Brown CJ. Mechanisms of X-chromosome inactivation. *Front Biosci*. 2006 Jan 1;11(1):852–66. doi:[10.2741/1842](https://doi.org/10.2741/1842)
95. Lujan HL, DiCarlo SE. Misunderstanding of race as biology has deep negative biological and social consequences. *Exp Physiol*. 2024 May 3;109(8):1240–3. doi:[10.1113/EP091491](https://doi.org/10.1113/EP091491) PubMed PMID: 38698766; PubMed Central PMCID: PMC11291859.
96. Chimps show much greater genetic diversity than humans | University of Oxford [Internet]. [cited 2026 Apr 10]. Available from: <https://www.ox.ac.uk/news/2012-03-02-chimps-show-much-greater-genetic-diversity-humans>
97. Human Genomic Variation [Internet]. [cited 2026 Apr 10]. Available from: <https://www.genome.gov/about-genomics/educational-resources/fact-sheets/human-genomic-variation>
98. Lewontin RC. The Apportionment of Human Diversity. In: Dobzhansky T, Hecht MK, Steere WC, editors. *Evolutionary Biology: Volume 6* [Internet]. New York, NY: Springer US; 1972 [cited 2026 Apr 10]. p. 381–98. Available from: https://doi.org/10.1007/978-1-4684-9063-3_14 doi:[10.1007/978-1-4684-9063-3_14](https://doi.org/10.1007/978-1-4684-9063-3_14)
99. Esoh K, Wonkam A. Evolutionary history of sickle-cell mutation: implications for global genetic medicine. *Hum Mol Genet*. 2021 Jan 18;30(R1):R119–28. doi:[10.1093/hmg/ddab004](https://doi.org/10.1093/hmg/ddab004) PubMed PMID: 33461216; PubMed Central PMCID: PMC8117455.
100. Hartge P, Struwing JP, Wacholder S, Brody LC, Tucker MA. The Prevalence of Common BRCA1 and BRCA2 Mutations among Ashkenazi Jews. *The American Journal of Human Genetics*. 1999 Apr 1;64(4):963–70. doi:[10.1086/302320](https://doi.org/10.1086/302320)
101. Sharma S, Mariño-Ramírez L, Jordan IK. Race, Ethnicity, and Pharmacogenomic Variation in the United States and the United Kingdom. *Pharmaceutics*. 2023 Jul 11;15(7):1923. doi:[10.3390/pharmaceutics15071923](https://doi.org/10.3390/pharmaceutics15071923) PubMed PMID: 37514109; PubMed Central PMCID: PMC10383154.
102. Duello TM, Rivedal S, Wickland C, Weller A. Race and genetics versus ‘race’ in genetics. *Evol Med Public Health*. 2021 Jun 15;9(1):232–45. doi:[10.1093/emph/eoab018](https://doi.org/10.1093/emph/eoab018) PubMed PMID: 34815885; PubMed Central PMCID: PMC8604262.
103. 1865: Mendel's Peas [Internet]. [cited 2026 Apr 10]. Available from: <https://www.genome.gov/25520230/online-education-kit-1865-mendels-peas>
104. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 3, Patterns Of Inheritance; p. 45–47.
105. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 3, Patterns of Inheritance, p. 40–45.

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use.

All clinical decisions should be made in consultation with qualified genetics professionals.

© 2026 Genomics Today – Pathology Final Project.

REFERENCE

References

106. Gulani A, Weiler T. Genetics, Autosomal Recessive. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 Apr 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK546620/> PubMed PMID: 31536227.
107. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 3, Patterns of Inheritance; p. 47-49
108. Basta M, Pandya AM. Genetics, X-Linked Inheritance. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 Apr 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK557383/> PubMed PMID: 32491315.
109. Cassidy SB, Schwartz S. Prader-Willi and Angelman syndromes. Disorders of genomic imprinting. Medicine (Baltimore). 1998 Mar;77(2):140-51. doi:10.1097/00005792-199803000-00005 PubMed PMID: 9556704.
110. Korf BR, Irons MB. Human genetics and genomics. Fourth edition. Chichester, West Sussex, UK: Wiley-Blackwell, a John Wiley & Sons, Ltd., Publication; 2013. Chapter 6, Cell Division and Chromosomes; p. 117-119.
111. Wallace SE, Bean LJ. Resources for Genetics Professionals – Genetic Disorders Caused by Imprinting Errors and Uniparental Disomy Not Detectable by Sequence Analysis. In: GeneReviews® [Internet] [Internet]. University of Washington, Seattle; 2017 [cited 2026 Apr 10]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK535150/>
112. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 6, Cell Division and Chromosomes; p. 54-57.
113. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 3, Patterns of Inheritance; p. 57-61.
114. Mei J, Ding P, Gao C, Zhou J, Li Z, Zhang C, et al. Mitochondrial Diseases: Molecular Pathogenesis and Therapeutic Advances. MedComm (2020). 2025 Sep;6(9):e70385. doi:10.1002/mco2.70385 PubMed PMID: 40949487; PubMed Central PMCID: PMC12426487.
115. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 5, Multifactorial Inheritance; p. 89-90.
116. Mitochondrial Disorders | National Institute of Neurological Disorders and Stroke [Internet]. [cited 2026 Apr 10]. Available from: <https://www.ninds.nih.gov/health-information/disorders/mitochondrial-disorders>
117. Copeland WC, Longley MJ. Mitochondrial genome maintenance in health and disease. DNA Repair (Amst). 2014 Jul;19:190-8. doi:10.1016/j.dnarep.2014.03.010 PubMed PMID: 24780559; PubMed Central PMCID: PMC4075028.
118. Chinnery PF. Primary Mitochondrial Disorders Overview. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2026 Apr 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1224/> PubMed PMID: 20301403.
119. Zhou Y, Kumari D, Sciascia N, Usdin K. CGG-repeat dynamics and FMR1 gene silencing in fragile X syndrome stem cells and stem cell-derived neurons. Mol Autism. 2016 Oct 6;7:42. doi:10.1186/s13229-016-0105-9 PubMed PMID: 27713816; PubMed Central PMCID: PMC5053128.
120. Timchenko LT, Tapscott SJ, Cooper TA, Monckton DG. Myotonic Dystrophy: Discussion of Molecular Basis. In: Madame Curie Bioscience Database [Internet] [Internet]. Landes Bioscience; 2013 [cited 2026 Apr 10]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK6512/>

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use. All clinical decisions should be made in consultation with qualified genetics professionals.

© 2026 Genomics Today – Pathology Final Project.

REFERENCE

References

121. Friedman JE. Anticipation in hereditary disease: the history of a biomedical concept. Hum Genet. 2011 Dec;130(6):705–14. doi:[10.1007/s00439-011-1022-9](https://doi.org/10.1007/s00439-011-1022-9) PubMed PMID: 21667285.
122. Human Chromosome Number | Learn Science at Scitable [Internet]. [cited 2026 Apr 10]. Available from: <http://www.nature.com/scitable/topicpage/human-chromosome-number-294>
123. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 6, Cell Division and Chromosomes; p. 104–107.
124. Chebly A. Cytogenetics in the genomics era: why karyotyping still matters. BMC Med Genomics. 2026 Jan 14;19:10. doi:[10.1186/s12920-025-02296-0](https://doi.org/10.1186/s12920-025-02296-0) PubMed PMID: 41535841; PubMed Central PMCID: PMC12801557.
125. Zhang S, He Y, Huang Y, Zhang Y, Du Y, Zhang T, et al. The accuracy and real resolution of karyotyping technique in detecting chromosomal aberrations identified by molecular genetic methods. Mol Genet Genomics. 2025 Aug 29;300(1):79. doi:[10.1007/s00438-025-02282-2](https://doi.org/10.1007/s00438-025-02282-2) PubMed PMID: 40879815.
126. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 6, Cell Division and Chromosomes, Figure 6.7; p 106
127. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 6, Cell Division and Chromosomes; p. 106–114.
128. Shakoori AR. Fluorescence In Situ Hybridization (FISH) and Its Applications. Chromosome Structure and Aberrations. 2017 Feb 10;343–67. doi:[10.1007/978-81-322-3673-3_16](https://doi.org/10.1007/978-81-322-3673-3_16) PubMed PMID: null; PubMed Central PMCID: PMC7122835.
129. Kurtovic-Kozaric A, Mehinovic L, Stomornjak-Vukadin M, Kurtovic-Basic I, Catibusic F, Kozaric M, et al. Diagnostics of common microdeletion syndromes using fluorescence in situ hybridization: Single center experience in a developing country. Bosn J Basic Med Sci. 2016 May;16(2):121–5. doi:[10.17305/bjbm.2016.994](https://doi.org/10.17305/bjbm.2016.994) PubMed PMID: 26937776; PubMed Central PMCID: PMC4852993.
130. So CC, Wan TSK, Yip SF, Chan LC. A dual colour dual fusion fluorescence in situ hybridisation study on the genesis of complex variant translocations in chronic myelogenous leukaemia. Oncol Rep. 2008 May;19(5):1181–4. PubMed PMID: 18425374.
131. Bhargava M. Chronic Myeloid Leukemia. In: Bhargava M, editor. Hematologic Malignancies: Case Studies in Cytogenetic and Molecular Genetics [Internet]. Singapore: Springer; 2021 [cited 2026 Apr 10]. p. 139–46. Available from: https://doi.org/10.1007/978-981-33-4799-1_7 doi:[10.1007/978-981-33-4799-1_7](https://doi.org/10.1007/978-981-33-4799-1_7)
132. Brown NA, Betz BL. Molecular Testing in Chronic Myelogenous Leukemia. In: Diagnostic Molecular Pathology [Internet]. Elsevier; 2017 [cited 2026 Apr 10]. p. 413–8. Available from: <https://linkinghub.elsevier.com/retrieve/pii/B9780128008867000327> doi:[10.1016/B978-0-12-800886-7.00032-7](https://doi.org/10.1016/B978-0-12-800886-7.00032-7)
133. Bejjani BA, Shaffer LG. Application of Array-Based Comparative Genomic Hybridization to Clinical Diagnostics. J Mol Diagn. 2006 Nov;8(5):528–33. doi:[10.2353/jmoldx.2006.060029](https://doi.org/10.2353/jmoldx.2006.060029) PubMed PMID: 17065418; PubMed Central PMCID: PMC1876176.
134. Korf BR, Irons MB. Human Genetics and Genomics. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 6, Cell Division and Chromosomes; p. 109.
135. Chaves TF, Oliveira LF, Ocampos M, Barbato IT, de Luca GR, Barbato Filho JH, et al. Long contiguous stretches of homozygosity detected by chromosomal microarrays (CMA) in patients with neurodevelopmental disorders in the South of Brazil. BMC Med Genomics. 2019 Mar 12;12:50. doi:[10.1186/s12920-019-0496-5](https://doi.org/10.1186/s12920-019-0496-5) PubMed PMID: 30866944; PubMed Central PMCID: PMC6417136.

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use. All clinical decisions should be made in consultation with qualified genetics professionals.
 © 2026 Genomics Today — Pathology Final Project.

REFERENCE

References

136. Boggula VR, Agarwal M, Kumar R, Awasthi S, Phadke SR. Recurrent benign copy number variants & issues in interpretation of variants of unknown significance identified by cytogenetic microarray in Indian patients with intellectual disability. *Indian J Med Res.* 2015 Dec;142(6):699–712. doi:[10.4103/0971-5916.174561](https://doi.org/10.4103/0971-5916.174561) PubMed PMID: 26831419; PubMed Central PMCID: PMC4774067.
137. Whatcott CJ, Posner RG, Von Hoff DD, Han H. Desmoplasia and chemoresistance in pancreatic cancer. In: Grippo PJ, Munshi HG, editors. *Pancreatic Cancer and Tumor Microenvironment* [Internet]. Trivandrum (India): Transworld Research Network; 2012 [cited 2026 Apr 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK98939/> PubMed PMID: 22876390.
138. Science [Internet]. 2021 [cited 2026 Apr 10]. The eccentric scientist behind the 'gold standard' COVID-19 test. Available from: <https://www.nationalgeographic.com/science/article/the-eccentric-scientist-behind-the-gold-standard-covid-19-pcr-test>
139. NobelPrize.org [Internet]. [cited 2026 Apr 10]. Nobel Prize in Chemistry 1993. Available from: <https://www.nobelprize.org/prizes/chemistry/1993/press-release/>
140. Korf BR, Irons MB. *Human Genetics and Genomics*. 4th ed. Chichester, West Sussex, UK: John Wiley & Sons; 2013. Chapter 2, Genetic Variation; p. 35.
141. Tahir MF, Ishtiaq S, Anas M, Irfan A, Jaremko M, Fahad S, et al. Integrating biotechnology into diagnostic labs: Innovations in PCR and molecular procedures. *Current Research in Biotechnology*. 2025 Jan 1;10:100325. doi:[10.1016/j.crbiot.2025.100325](https://doi.org/10.1016/j.crbiot.2025.100325)
142. Sanger Sequencing: Introduction, Principle, and Protocol | CD Genomics Blog [Internet]. [cited 2026 Apr 10]. Available from: <https://www.cd-genomics.com/blog/sanger-sequencing-introduction-principle-and-protocol/>
143. Satam H, Joshi K, Mangrolia U, Wagahoo S, Zaidi G, Rawool S, et al. Next-Generation Sequencing Technology: Current Trends and Advancements. *Biology (Basel)*. 2023 Jul 13;12(7):997. doi:[10.3390/biology12070997](https://doi.org/10.3390/biology12070997) PubMed PMID: 37508427; PubMed Central PMCID: PMC10376292.
144. Brlek P, Bulić L, Bračić M, Projić P, Škaro V, Shah N, et al. Implementing Whole Genome Sequencing (WGS) in Clinical Practice: Advantages, Challenges, and Future Perspectives. *Cells*. 2024 Mar 13;13(6):504. doi:[10.3390/cells13060504](https://doi.org/10.3390/cells13060504)
145. Federico C, Bruno F, Ragusa D, Clements CS, Brancato D, Henry MP, et al. Chromosomal Rearrangements and Altered Nuclear Organization: Recent Mechanistic Models in Cancer. *Cancers (Basel)*. 2021 Nov 22;13(22):5860. doi:[10.3390/cancers13225860](https://doi.org/10.3390/cancers13225860) PubMed PMID: 34831011; PubMed Central PMCID: PMC8616464.
146. Al-Achkar W, Wafa A, Ikhtiar A, Liehr T. Three-way Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2) as a secondary abnormality in an imatinib mesylate-resistant chronic myeloid leukemia patient. *Oncol Lett*. 2013 May;5(5):1656–8. doi:[10.3892/ol.2013.1228](https://doi.org/10.3892/ol.2013.1228) PubMed PMID: 23759955; PubMed Central PMCID: PMC3678570.
147. Koretzky GA. The legacy of the Philadelphia chromosome. *J Clin Invest*. 2007 Aug 1;117(8):2030–2. doi:[10.1172/JCI33032](https://doi.org/10.1172/JCI33032) PubMed PMID: 17671635; PubMed Central PMCID: PMC1934583.
148. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. *Blood*. 2005 Apr 1;105(7):2640–53. doi:[10.1182/blood-2004-08-3097](https://doi.org/10.1182/blood-2004-08-3097)
149. PDQ Pediatric Treatment Editorial Board. Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®): Health Professional Version. In: *PDQ Cancer Information Summaries* [Internet]. Bethesda (MD): National Cancer Institute (US); 2002 [cited 2026 Apr 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK65842/> PubMed PMID: 26389282.
150. WAGR Syndrome/11p Deletion Syndrome - Symptoms, Causes, Treatment | NORD [Internet]. [cited 2026 Apr 10]. Available from: <https://rarediseases.org/rare-diseases/wagr-syndrome11p-deletion-syndrome/>

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use.

All clinical decisions should be made in consultation with qualified genetics professionals.

© 2026 Genomics Today — Pathology Final Project.

REFERENCE

References

151. Duffy KA, Trout KL, Gunckle JM, Krantz SM, Morris J, Kalish JM. Results From the WAGR Syndrome Patient Registry: Characterization of WAGR Spectrum and Recommendations for Care Management. *Front Pediatr*. 2021 Dec 14;9:733018. doi:[10.3389/fped.2021.733018](https://doi.org/10.3389/fped.2021.733018) PubMed PMID: 34970513; PubMed Central PMCID: PMC8712693.
152. About WAGR - What is WAGR Syndrome [Internet]. [cited 2026 Apr 10]. Available from: <https://wagr.org/what-is-wagr-syndrome>
153. Sankari A, Sharma S. Cystic Fibrosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 Apr 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK493206/> PubMed PMID: 29630258.
154. Winiarska HM, Springer D, Wojtaś F, Wysocka E, Cofta S. CFTR Modulators Therapy Efficacy in Reducing Cystic Fibrosis (CF) Exacerbation and Improving Selected Spirometry Parameters: A Real-Life Study in a Single-Centre Polish Population. *Journal of Clinical Medicine*. 2024 Jan;13(15):4491. doi:[10.3390/jcm13154491](https://doi.org/10.3390/jcm13154491)
155. Arning L, Nguyen HP. Huntington disease update: new insights into the role of repeat instability in disease pathogenesis. *Med Genet*. 33(4):293–300. doi:[10.1515/medgen-2021-2101](https://doi.org/10.1515/medgen-2021-2101) PubMed PMID: 38835439; PubMed Central PMCID: PMC11006308.
156. Oosterloo M, Touze A, Byrne LM, Achenbach J, Aksoy H, Coleman A, et al. Clinical Review of Juvenile Huntington's Disease. *J Huntingtons Dis*. 13(2):149–61. doi:[10.3233/JHD-231523](https://doi.org/10.3233/JHD-231523) PubMed PMID: 38669553; PubMed Central PMCID: PMC11307030.
157. Sampaio C, Levey J, Klitzman R. PREDICTIVE TESTING AND CLINICAL TRIALS IN HUNTINGTON'S DISEASE: AN ETHICAL ANALYSIS. *Mov Disord*. 2018 Feb;33(2):243–7. doi:[10.1002/mds.27247](https://doi.org/10.1002/mds.27247) PubMed PMID: 29205501; PubMed Central PMCID: PMC5854324.
158. Ballard LM, Doheny S, Dimond R, Lucassen AM, Clarke AJ. Predictive genetic testing for Huntington's disease: Exploring participant experiences of uncertainty and ambivalence between clinic appointments. *J Genet Couns*. 2025 Feb;34(1):e1911. doi:[10.1002/jgc4.1911](https://doi.org/10.1002/jgc4.1911) PubMed PMID: 38741209; PubMed Central PMCID: PMC11735177.
159. Kumari D, Somma V, Nakamura AJ, Bonner WM, D'Ambrosio E, Usdin K. The role of DNA damage response pathways in chromosome fragility in Fragile X syndrome. *Nucleic Acids Res*. 2009 Jul;37(13):4385–92. doi:[10.1093/nar/gkp391](https://doi.org/10.1093/nar/gkp391) PubMed PMID: 19465392; PubMed Central PMCID: PMC2715245.
160. Shah M, Los E. Fragile X Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 Apr 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK459243/> PubMed PMID: 29083768.
161. Hogan AJ. Visualizing carrier status: Fragile X syndrome and genetic diagnosis since the 1940s. *Endeavour*. 2012 Jun 1;36(2):77–84. doi:[10.1016/j.endeavour.2011.12.002](https://doi.org/10.1016/j.endeavour.2011.12.002)
162. Crawford DC, Acuña JM, Sherman SL. FMR1 and the fragile X syndrome: Human genome epidemiology review. *Genetics in Medicine*. 2001 Sep 1;3(5):359–71. doi:[10.1097/00125817-200109000-00006](https://doi.org/10.1097/00125817-200109000-00006)
163. Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, et al. The Fragile X Syndrome Protein FMRP Associates with BC1 RNA and Regulates the Translation of Specific mRNAs at Synapses. *Cell*. 2003 Feb 7;112(3):317–27. doi:[10.1016/S0092-8674\(03\)00079-5](https://doi.org/10.1016/S0092-8674(03)00079-5)
164. Nowell PC. Discovery of the Philadelphia chromosome: a personal perspective. *J Clin Invest*. 2007 Aug 1;117(8):2033–5. doi:[10.1172/JCI31771](https://doi.org/10.1172/JCI31771) PubMed PMID: 17671636; PubMed Central PMCID: PMC1934591.
165. Haider MZ, Anwer F. Genetics, Philadelphia Chromosome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 Apr 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK560689/> PubMed PMID: 32809524.

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use. All clinical decisions should be made in consultation with qualified genetics professionals.
 © 2026 Genomics Today — Pathology Final Project.

REFERENCE

References

166. Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. *Leukemia*. 2018 May;32(5):1135–46. doi:[10.1038/s41375-017-0005-9](https://doi.org/10.1038/s41375-017-0005-9)
167. Grinstein JD. The Immaculate Conception of Gleevec, As Told by Brian Druker. *GEN - Genetic Engineering and Biotechnology News* [Internet]. 2023 Apr 25 [cited 2026 Apr 10]. Available from: <https://www.genengnews.com/topics/cancer/the-immaculate-conception-of-gleevec-as-told-by-brian-druker/>
168. Iqbal N, Iqbal N. Imatinib: A Breakthrough of Targeted Therapy in Cancer. *Chemother Res Pract*. 2014;2014:357027. doi:[10.1155/2014/357027](https://doi.org/10.1155/2014/357027) PubMed PMID: 24963404; PubMed Central PMCID: PMC4055302.
169. Soverini S. Resistance mutations in CML and how we approach them. *Hematology Am Soc Hematol Educ Program*. 2023 Dec 8;2023(1):469–75. doi:[10.1182/hematology.2023000447](https://doi.org/10.1182/hematology.2023000447)
170. Hermans A, Heisterkamp N, Lindern M von, Baal S van, Meijer D, Plas D van der, et al. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. *Cell*. 1987 Oct 9;51(1):33–40. doi:[10.1016/0092-8674\(87\)90007-9](https://doi.org/10.1016/0092-8674(87)90007-9) PubMed PMID: 2820585.
171. Drugs.com [Internet]. [cited 2026 Apr 10]. Sprycel (dasatinib) FDA Approval History. Available from: <https://www.drugs.com/history/sprycel.html>
172. Levin J. ARIAD Announces Accelerated Approval by FDA of Iclusig (Ponatinib) for Patients with CML and Ph+ ALL Resistant or Intolerant to Prior Tyrosine Kinase Inhibitor Therapy | Fierce Biotech [Internet]. 2012 [cited 2026 Apr 10]. Available from: <https://www.fiercebiotech.com/biotech/ariad-announces-accelerated-approval-by-fda-of-iclusig-ponatinib-for-patients-cml-and-ph>

REFERENCE

Image References In Order of Appearance

1. Unsplash. Photo by Ryoji Iwata on Unsplash [Internet]. 2017 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/peoples-walking-on-pedestrian-lane-X53e51WfjIE>
2. Willingham E. Genes May Influence COVID-19 Risk, New Studies Hint. Scientific American [Internet]. [cited 2026 Apr 10]. Available from: <https://www.scientificamerican.com/article/genes-may-influence-covid-19-risk-new-studies-hint/>
3. Reardon S. A complete human genome sequence is close: how scientists filled in the gaps. Nature. 2021 Jun 4;594(7862):158–9. doi:10.1038/d41586-021-01506-w
4. Most tumors in body share important mutations. National Institutes of Health (NIH) [Internet]. [cited 2026 Apr 10]. Available from: <https://www.nih.gov/news-events/nih-research-matters/most-tumors-body-share-important-mutations>
5. Tumor DNA in Blood May Signal Immunotherapy Response. NCI Cancer Currents Blog [Internet]. 2016 [cited 2026 Apr 10]. Located at: nciglobal, ncicenterprise. Available from: <https://www.cancer.gov/news-events/cancer-currents-blog/2016/ctdna-immunotherapy-response>
6. Unsplash. Photo by Ryoji Iwata on Unsplash [Internet]. 2018 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/crowding-people-crossing-on-pedestrian-lane-CLZ5DzbbhG0>
7. UK CR. Thinking outside the chromosome – how ecDNA is challenging conventional thinking. Cancer Research UK - Cancer News [Internet]. 2022 Nov 11 [cited 2026 Apr 10]. Available from: <https://news.cancerresearchuk.org/2022/11/11/thinking-outside-the-chromosome-how-ecdna-is-challenging-conventional-thinking/>
8. Unsplash. Photo by National Cancer Institute on Unsplash [Internet]. 2019 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/a-close-up-of-a-cell-phone-with-a-black-background-J28Nn-CDbII>
9. Unsplash. Photo by National Cancer Institute on Unsplash [Internet]. 2019 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/purple-cells-L7en7Lb-Ovc>
10. Unsplash. Photo by National Cancer Institute on Unsplash [Internet]. 2021 [cited 2026 Apr 10]. Available from: https://unsplash.com/photos/a-close-up-of-a-cell-phone-with-a-blue-background-IPpyUZceg_I
11. Nagy A, Nagy K. The mysteries of induced pluripotency: where will they lead? Nat Methods. 2010 Jan;7(1):22–4. doi:10.1038/nmeth.f.292
12. Unsplash. Photo by Jonathan Borba on Unsplash [Internet]. 2023 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/a-woman-holding-a-baby-in-her-lap-V3Dyo50x4Hc>
13. Alloul CA. Opioids: Question before you trust. Excalibur [Internet]. 2025 Mar 13 [cited 2026 Apr 10]. Available from: <https://www.excal.on.ca/health/2025/03/13/opioids-question-before-you-trust/>
14. Unsplash. Photo by National Cancer Institute on Unsplash [Internet]. 2021 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/blue-and-white-abstract-painting-I-F4ibaAtLA>
15. Unsplash. Photo by Ryoji Iwata on Unsplash [Internet]. 2019 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/aerial-photography-of-man-and-woman-walking-on-pedestrian-lane-during-daytime-2OalKackLvU>

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use. All clinical decisions should be made in consultation with qualified genetics professionals.

© 2026 Genomics Today — Pathology Final Project.

REFERENCE

Image References

16. Unsplash. Photo by National Cancer Institute on Unsplash [Internet]. 2021 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/red-and-white-abstract-painting-jdfn7Z03Qa4>
17. Kolata G. Two New Drugs Help Relieve Sickle-Cell Disease. But Who Will Pay? The New York Times [Internet]. 2019 Dec 7 [cited 2026 Apr 10]. Available from: <https://www.nytimes.com/2019/12/07/health/sickle-cell-adakveo-oxbryta.html>
18. How the Human Genome Project revolutionised biology. The Economist [Internet]. [cited 2026 Apr 10]. Available from: <https://www.economist.com/science-and-technology/2023/04/08/how-the-human-genome-project-revolutionised-biology>
19. Unsplash. Photo by National Cancer Institute on Unsplash [Internet]. 2021 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/black-pink-and-blue-floral-textile-c-wqrSCjVf4>
20. Unsplash. Photo by National Cancer Institute on Unsplash [Internet]. 2021 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/pink-and-purple-floral-textile-4zA4w-dr5WM>
21. What's Wrong With This Picture 2? KI Image Awards Archive [Internet]. [cited 2026 Apr 10]. Available from: <https://ki-images.mit.edu/2016/santaguida-2>
22. Study helps explain varying outcomes for cancer, Down Syndrome. MIT News | Massachusetts Institute of Technology [Internet]. 2017 [cited 2026 Apr 10]. Available from: <https://news.mit.edu/2017/chromosome-number-varying-outcomes-cancer-down-syndrome-0406>
23. The More the Messier: Understanding Complicated Cell Division. KI Image Awards Archive [Internet]. [cited 2026 Apr 10]. Available from: <https://ki-images.mit.edu/2014/knouse>
24. Unsplash. Photo by National Cancer Institute on Unsplash [Internet]. 2021 [cited 2026 Apr 10]. Available from: https://unsplash.com/photos/blue-and-black-round-illustration-u17jQ_hPWUY
25. Unsplash. Photo by Ryoji Iwata on Unsplash [Internet]. 2017 [cited 2026 Apr 10]. Available from: https://unsplash.com/photos/aerial-view-photography-of-group-of-people-walking-on-gray-and-white-pedestrian-lane-n3lJPLu8_Pw
26. Molecular Testing in Chronic Myelogenous Leukemia. In: Diagnostic Molecular Pathology [Internet]. Academic Press; 2017 [cited 2026 Apr 10]. p. 413–8. Available from: <https://www.sciencedirect.com/science/chapter/edited-volume/abs/pii/B9780128008867000327>
doi:10.1016/B978-0-12-800886-7.00032-7
27. Marshall E. Cancer Gene Data Casts Doubt on Popular Research Method. Science. 2012 Nov 2;338(6107):593–593. doi:10.1126/science.338.6107.593
28. Unsplash. Photo by National Cancer Institute on Unsplash [Internet]. 2021 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/purple-and-blue-heart-illustration-irmUWEcjIz4>
29. Unsplash. Photo by National Cancer Institute on Unsplash [Internet]. 2021 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/white-and-black-abstract-painting-ERdyFahv-GU>
30. Unsplash. Photo by Ryoji Iwata on Unsplash [Internet]. 2019 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/aerial-view-of-people-walking-on-cross-pedestrian-lane-TRJjPcOwssQ>

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use. All clinical decisions should be made in consultation with qualified genetics professionals.

© 2026 Genomics Today — Pathology Final Project.

REFERENCE

Image References

31. WAGR Syndrome: Background, Epidemiology, Etiology [Internet]. 2026 Mar 17 [cited 2026 Apr 10]. Available from: <https://emedicine.medscape.com/article/989329-overview>
32. Huntington's Double-Edged Sword [Internet]. [cited 2026 Apr 10]. Available from: <https://www.science.org/content/article/huntingtons-double-edged-sword>
33. How Huntington's disease affects different neurons. Brain and Cognitive Sciences [Internet]. [cited 2026 Apr 10]. Available from: <https://bcs.mit.edu/news/how-huntingtons-disease-affects-different-neurons>
34. Altered visual processing in a mouse model of fragile X syndrome; and more. The Transmitter: Neuroscience News and Perspectives [Internet]. 2025 [cited 2026 Apr 10]. Available from: <https://www.thetransmitter.org/spectrum/altered-visual-processing-in-a-mouse-model-of-fragile-x-syndrome-and-more/>
35. Unsplash. Photo by Ryoji Iwata on Unsplash [Internet]. 2019 [cited 2026 Apr 10]. Available from: <https://unsplash.com/photos/birds-eye-view-photography-of-people-crossing-street-HDbavxACggA>
- 36.

This magazine was produced as an educational resource for a Pathology final project and is not intended for clinical use. All clinical decisions should be made in consultation with qualified genetics professionals.

© 2026 Genomics Today — Pathology Final Project.

GENOMICS TODAY

Molecular Genetics & Cytogenomic Disorders

PATHOLOGY FINAL PROJECT • 2026

GT